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Abstract 
1,3-β-glucans are a class of natural polysaccharides with unique pharmacological 
properties and the ability to form triple helical structures and resilient gels. Curdlan and other 
1,3-β-glucans have found application pharmacologically in the treatment of cancers and 
acceleration of wound healing in humans and in the impartation of infection resistance in animal 
husbandry. Structurally, these polysaccharides have found application in food science as thermal 
gels, in nanostructure formation as helical scaffolds, and in drug delivery as nanocarriers for 
drugs and as inclusion complexes with polynucleotides.  
A literature review of the important work on Curdlan research reveals two streams of 
research: investigation of the pharmacological significance of these polymers and their 
application in increasing host immunocompetency and investigation of the nature of the triple 
helix and its application in a variety of fields from food gels to drug delivery. Two significant 
contributions to the field of Curdlan research have been completed including 1) The 
development of a Curdlan nanoparticle drug delivery platform and 2) A new multi-component 
liquid crystalline hydrogel providing a new route to form polynucleotide inclusion complexes 
with Curdlan for gene delivery. The developed nanoparticle platform exhibited high 
encapsulation of chemotherapeutic drugs and a 24-hour controlled release with a particle size of 
109.9 nm. The liquid crystalline hydrogel exhibited homogeneous inclusion of DNA into 
amorphous and crystalline phases of Curdlan and delayed and triggered release of polynucleotide 
content. This work has been a significant demonstration of the potential of Curdlan as a new 
polymer for multi-functional drug delivery. 
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1.0 General Introduction 
Modern drug delivery techniques seek to alter the pharmacokinetics and 
pharmacodynamics of drug substances such as pharmaceuticals, chemotherapeutics, peptides, or 
genes (polynucleotides) in the human body. Modulation of pharmacokinetics targets the 
absorption, distribution, metabolism, and elimination of drug substances in the body and 
modulation of pharmacodynamics alters the uptake of drugs into cells and the overall effect of 
the drug substance.  
Alteration to the absorption, distribution, metabolism, and elimination (ADME) of a drug 
substance is most often accomplished using controlled release technologies. These technologies 
typically utilize encapsulation by a biocompatible substance that acts as a diffusional barrier to 
provide controlled release, degrades over time to provide delayed release, or has a specific 
triggered mechanism of degradation to provide triggered release. Modulation of 
pharmacodynamics typically alters the interactions occurring between the drug substance and the 
body. In terms of the extent of interactions, drug delivery systems seek to ensure that drug 
interactions with the body occur only at the intended site of action, reducing side effects and 
patient suffering. For example, in the case of chemotherapy, systemic distribution of 
chemotherapeutics results in widespread destruction of fast-growing cells including cancer cells, 
immune cells, and hair follicles causing devastating side effects. Drug delivery systems typically 
reduce unintended drug interactions through encapsulation of the substance and the use of 
targeting mechanisms such as receptor-ligand interactions to ensure the drug payload is delivered 
to the intended site. In terms of cellular uptake, the use of a targeting mechanism in a receptor-
ligand relationship can improve the cellular uptake of a substance. Simultaneous delivery of an 
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adjuvant substance to boost the cellular uptake of the drug is also an popular approach, especially 
in the case of delivery of adjuvants to boost the effect of vaccines.  
This thesis describes work done in the development of polymer nanoparticle drug 
delivery system and a polymer hydrogel gene delivery system. These two examples of drug 
delivery systems are described next as a general introduction.  
1.1 Polymer Nanoparticle Delivery Systems 
Drug delivery systems have a number of manifestations that seek to accomplish the goals 
of improving pharmacokinetics and pharmacodynamics. Polymer nanoparticle drug delivery 
systems use nanocapsules to alter the pharmacokinetics and pharmacodynamics of a drug 
substance by providing a biocompatible polymer coating that affords controlled release and 
restricts unintended exposure to the body1. Copolymer nanoparticle systems are especially 
popular as they utilize the self-assembly of an amphiphilic copolymer to form core-shell micelles 
wherein the internal core is typically hydrophobic and the outer shell in hydrophilic. Since many 
drug substances are hydrophobic and proteins in the body show less adsorbance on hydrophilic 
surfaces, the system acts as an ideal nanocapsule that holds a drug payload in its core and 
provides a ‘stealth’ effect from the immune system. Furthermore, the size of polymer micelles 
are typically less than 200 nm, affording the use of the enhanced permeability and retention 
effect (EPR) that allows targeting of leaky tumor vasculature by size alone without the need for a 
targeting mechanism2, 3. A number of literature reviews exist of trends in polymer nanoparticle 
drug delivery1, 4-7.  
1.2 Hydrogel Drug Delivery Systems 
Hydrogel systems are typically cross-linked polymer networks that entrap drug 
substances amongst their fibers and provide controlled release through network swelling and 
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contraction or dissolution of cross-links in response to external stimuli such as pH or 
temperature. These systems are particularly attractive as they often use hydrophilic polymers that 
allow water swelling, providing excellent biocompatibility. Hydrogels may be formed into 
nanoparticles and used in systemic distribution as with other polymer nanoparticle systems8 but 
they also provide unique applications in oral drug delivery due to their pH sensitivity and in the 
direct injection into sites of action due to their temperature sensitivity9. For example, direct 
injection into joints affords a temperature change from ambient room temperature to body 
temperature of 37 °C that can result in gel swelling to release drug substances packed into the 
fibrous network or alternatively yield gel contraction to provide a controlled release effect as the 
hydrogel degrades. Polysaccharides such as alginates that cross-link with calcium ions to form 
hydrogels have been studied extensively for drug delivery applications10.  
1.3 Natural Polysaccharides with Biomedical Properties 
Natural polysaccharides are an especially promising research direction in polymer drug 
delivery and biomedical applications because they are so abundant in nature, are often naturally 
biocompatible, and they typically provide additional properties that aren’t attainable from 
synthetic polymers. Notable examples are cellulose from wood or bacterial sources now used in 
novel bandage materials to speed wound healing11, chitosan from shrimp shells with 
mucoadhesive properties that can facilitate ocular drug delivery12, 13, and alginates from kelp that 
form hydrogels suitable as scaffolds for model extracellular matrices14or protein delivery 
vehicles that avoid protein denaturation during gelation10. 
1.4 The Family of 1,3-Beta-Glucans and Curdlan 
1,3-β-glucans are a class of glucopyranose polysaccharides with (1,3) glycosidic linkages 
(Fig 1) and varying degrees of (1,6) branching obtained from fungal15 or microbial sources16. An 
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illustration of the fungal cell wall adapted from electron micrographs of Candida Albicans17 
demonstrates the natural presence of β-glucans in fungi (Fig 2). 1,3-β-glucans form helical 
structures that may be prompted to gel with the addition of heat and have a unique ability to 
increase host immunocompetency. Reported pharmacological effects include anti-tumor 




Figure 1. Schematic of a 1,3-Beta-Glucan. (Top) Schematic of 1,3-β-glucans consisting of 
glucopyranose monomers joined by glycosydic ether linkages between C(1) and C(3) in the 
glucopyranose rings and branch points often occur periodical in the (1,6) configuration. 
(Bottom) Numbering of carbons in glucose. 
 
 
Figure 2. Schematic of a Fungal Cell Wall17. Adapted schematic of the fungal cell wall 
containing a composite of chitin and β-glucans with interspersed mannoproteins (spheres) 
surrounding the phospholipid membrane. 
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The formation of 1,3-β-glucan helical domains may be utilized for many applications or, 
as the helices natural cross-link through hydrogen bonding, be allowed to continue to the 
formation of a hydrogel network. The gelation profile is dependent on the degree of branching 
due to the effect of C(6) branching on helix packing26. Curdlan, a linear 1,3-β-glucan, has been 
used as a good model for the study of 1,3-β-glucan helical structures as it lacks the interference 
of periodic branching27, 28. The unique properties of 1,3-β-glucans have led to a variety of 
applications including the formulation of food gels for consumption or to improve stability and 
nutrition29, 30, direct therapeutic application31, 32, encapsulation and controlled release of various 
bioactive species33, 34, and application as helical scaffolds for nanostructure formation35, 36. 
This thesis focuses on the demonstration of Curdlan 1,3-beta-glucans as a new platform 
for polymer drug delivery. Before establishing specific objectives for contributions to the 
literature, a comprehensive literature review is provided. This review begins with a discussion of 
the physical properties and gelation capabilities of 1,3-beta-glucans, using Curdlan as the 
primary example as has been the trend in the literature due to its lack of interfering branching 
effects. The review then describes the bioactivity of 1,3-beta-glucans as a whole and reviews all 
the relevant applications that have been developed using this family of polysaccharides. 
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2.0 Literature Review 
2.1 Physical Properties of Curdlan 1,3-β-glucans 
Curdlan was first discovered as a resilient gel forming polysaccharide bearing β-
glycosydic linkages that was biosynthesized from the soil bacterium Alcaligenes faecalis var. 
myxogenes in the mid-1960’s37, 38. Curdlan was found to be a linear 1,3-β-glucan that was 
insoluble in water but soluble in alkaline solutions. Experimentation with the gelation 
characteristics of Curdlan began shortly afterwards39, 40. Alkaline solutions inhibit hydrogen 
bonding between C(2) hydroxyls, inhibiting helix formation, leaving the random coil state. 
Commercial alkali treatment leaves most available Curdlan powder < 30% crystalline with a 
prevalence of a mixture of random coils and some single and triple helices41. This partially 
crystalline native form may be thermally treated in water to induce hydrogen bonded crystallinity 
and the incorporation of water molecules into helical structures to form a hydrogel. This 
hydrated, crystallized form may then be dehydrated to further improve crystallinity and re-
swelled at will.  
2.1.1 Helical Conformations in Curdlan 
Helical polysaccharide structures held together by O(2) hydrogen bonding in 1,3-linked 
polysaccharides were hypothesized in 196842. As stated previously, Curdlan may form both 
single helical and triple helical structures with some disagreement in the literature as to the 
relative populations of these species43. Single helices form via intra-chain hydrogen bonding 
between O(2) hydroxyls on glucopyranose residues44. Gelation of Curdlan causes single helices 
to rearrange hydrogen bonds to form inter-strand hydrogen bonding and hence the formation of 
the triple helix. 
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X-ray Diffraction uncovered the first evidence of the triple helical structures in gelled and 
dehydrated Curdlan. A right-handed triple helical model was assigned with six glucose residues 
per turn and a monomer advance of 2.935 Å (Fig 3; top) 27. A model projection of the Curdlan 
triple helix is shown in (Fig 3b; top) with the six glucose residues (two from each single helix) in 
each turn44. The periodic crystal of Curdlan shows four triple helices associating via O(4) and 
O(6) hydrogen bonding to produce longer-range order (Fig 4). The unit cell would be drawn as a 
parallelogram from the centre of each of the four helices, showing the presence of six glucose 
residues in the unit cell. It is of interest to note that the hydroxymethyl groups on C(6) decorate 
the outside of the triple helices, not affecting internal structure but being critical for longer-range 
order. For applications then, functionalization at the C(6) position would be inconsequential to 
the triple helices themselves but may change the overall crystallinity and gelation profile27. 
Investigation of hydrated Curdlan in comparison to the dehydrated form began in 1983. 
The crystalline arrangements were similar between the two forms except for the dimensions of 
the unit cell showing an increased fiber repeat parameter, indicating a loss of symmetry and an 
increase in the volume of the unit cells in the hydrated state. The increased volume was 
suggestive of the incorporation of significant amounts of water into the triple helix. 
Approximately 18 to 36 molecules of water were found per unit cell that all contributed 





Figure 3. Hydrogen Bonding Schemes for the Curdlan Triple Helix44. (Top) Original Right-
Handed Triple Helix with Inter-Strand H-Bonding, (Middle) Left-Handed Triple Helix with 
Inter-Strand Bonding, and (Bottom) Right-Handed Triple Helix with Intra-Strand H-Bonding, 
(a) Model of Triple Helical Formation, (b) X-Y Projection of helical strands. 
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Figure 4. Periodicity in Highly Crystalline Curdlan. Four triple helices held by hydrogen 
bonding between O(4) and O(6) oxygens, 
 
Although these studies are generally considered conclusive as to the crystallographic 
forms of Curdlan, there still exists some controversy. The presence of two additional hydrogen 
bonding schemes have been postulated. Besides the originally proposed inter-strand hydrogen 
bonding (Fig 3; top), the association of single helices without inter-strand hydrogen bonding, 
instead relying on Van der Waals forces to maintain the triple helix, has been found to be 
favorable via simulation based on an improvement in the linearity of the H-bond, despite an 
unfavorable increase in bond length (Fig 3; bottom). A third H-bonding scheme that maintains 
inter-strand bonding to hold the triple helix together but requires O(2) H-bonds with adjacent 




right-handed helix (Fig 3; middle). Considering heat of formation and bond energy, the new 
hydrogen bonding structures were thermodynamically favored in simulation44. The existence of 
these new hydrogen bonding structures have not yet been verified experimentally but they offer 
insight into the transition of bonds that may occur during crystallization as single helices 
aggregate and rearrange hydrogen bonds to form triple helices.  
2.1.2 Current Understanding of Curdlan Gelation 
Curdlan gels have been studied since 1967 wherein gelation was observed above 55 °C 
when heated from aqueous or dilute alkaline solutions40. Curdlan gels may be obtained by simply 
hydrating Curdlan under heating or by neutralization from alkali solution41. The general methods 
for the gelation of Curdlan follow (Table 1).  
Table 1. Methods of Curdlan Gelation 
Type Crystallinity Method 
Native < 30% N/A 
Curdlan Hydrate High 
55-145 °C in Humidity or from Suspension 
Neutralization of Alkaline Solution 
Dry Curdlan Very High Dry Curdlan Hydrate 
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Gelation is normally carried out from 10% (w/v) suspensions in water, dilute alkaline 
solution, buffer45 or with 10% solutions in DMSO that are extruded into methanol and dried 
before heating under humidity27. Gelation can be separated into two distinct regimes. Treatment 
between 55-80 °C induces the formation of a low-set gel. Low-set gels may dissociate upon 
cooling but they may be further treated to strengthen the gel into the next regime. Treatment 
between 80-145 °C induces the formation of a thermally irreversible high-set gel that will not 
melt and cannot be further crystallized once cooled45. Gelation is also possible by neutralizing a 
0.1 M NaOH solution of Curdlan with 0.1 M HCl and purifying the gel suspension by dialysis46. 
Dissolution of crystalline Curdlan may be carried out using DMSO, a good solvent for Curdlan 
that disrupts hydrogen bonds or by increasing alkaline concentration47, 48. The gelation 
mechanism of Curdlan has been heavily investigated in the literature (Table 2). 
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Table 2. Characterization Techniques for Curdlan Gelation 
Method Parameter(s) Reference 
Nuclear Magnetic Resonance 13C Peak Intensity and Width 43 
Electron Microscopy Direct Observation 46 
Differential Scanning 
Calorimetry Enthalpy Change 
49 
Attenuated Total Reflection 
Infrared Spectroscopy Infrared Band Shifts 
45 
Rheology Storage Modulus 41 
Nuclear Magnetic Resonance 
Relaxometry Chain Mobility 
41 
Atomic Force Microscopy Direct Observation 50 
Single Molecule Force 
Spectrsoscopy Interaction Forces 
51 
 
13C Nuclear Magnetic Resonance (NMR) has been used to observe the proportions of 
single to triple helices in Curdlan gels formed from aqueous and dilute alkaline suspensions. 
Significant line broadening for the six carbon peaks between 60-100 ppm occurred due to the 
lack of chain mobility in the triple helical structures (Fig 5; Left) with these peaks sharpening 
slightly as the alkaline concentration was increased and then drastically sharpening around 0.22 
M NaOH, indicative of the formation of random coils (Fig 5; Right). This behavior is consistent 
with studies on the loss of crystallinity in alkaline solutions48. Downfield peak shifts of C(1), 
C(3), and C(4) during gelation verified the formation of an ordered helical structure as these 
shifts were ascribed to a restriction in rotational motion of the glycosydic linkage and the 
development of hydrogen bonding between helices. Since it was reasoned that the entirety of the 
13C signal was due to single helical structures due to the immobilization of chains in multiple-
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helical networks it was concluded that Curdlan gels might contain more significant populations 




Figure 5. NMR Peak Broadening and Effect of Alkaline Concentration43. The six 13C-NMR 
Peaks of Curdlan show significant broadening when moving from Native Curdlan (Left: 
Bottom) to the Resilient Gel (Left: Top) and the peaks sharpen when exposed to increasing 
concentrations of NaOH solution (Right): (A) Aqueous Suspension, (B) 0.06 M, (C) 0.19 M, and 
(D) 0.22 M. 
 
Electron Microscopy (EM) has been used to obtain images of the gelling behavior of 
Curdlan. SEM images revealed 30 Å fibrils in 100-200 Å bundles with micrographs clearly 
showing the similarity in helical conformations formed by heating to low-set gels and 
neutralization, both forming rope like Curdlan fibers (Fig 6A,B). Images of samples heated to 90 
°C after heating at 60 °C (Fig 6C) demonstrated that low-set gels may be further crystallized to 
high-set gels. Re-heating at higher temperatures (120 °C) resulted in a return to the less ordered 








hydrogen bonds that initially break when heated to release microfibrils and then reorganize to 
rebuild greater crystallinity. High-set gels were believed to gain additional strength from 
hydrophobic interactions46. 
 
Figure 6. Electron Micrographs of Curdlan Gels46. (A) Curdlan gelled by Neutralization 
shows 100-200 angstrom bundles with (B) Heating to low-set gel at 60 °C improving 
crystallinity, (C) Re-heating at 90 °C showing further increases into the high-set regime, and (D) 
Re-heating at 120 °C showing a decrease in crystallinity. 
 
Differential Scanning Calorimetry (DSC) demonstrated the temperature-induced gelation 
of Curdlan in an aqueous suspension. Endothermic swelling was observed at 56 °C, highest 
 16 
crystallization at 142 °C, and melting of the gel at 154 °C (Fig 7). Thus, low-set, thermally 
reversible gels that may be further crystallized are created in the temperature range of 60-80 °C, 
containing small amounts of triple helices and high-set, thermally irreversible gels are created at 
temperatures up to 150 °C with much higher crystallinity49. 
 
Figure 7. Differential Scanning Calorimetry Study of Curdlan49. DSC of a 4% aqueous 
suspension reveals an initial endothermic event at 56 °C as Curdlan is heated to a low-set gel and 
another event at 142 °C when Curdlan reaches its highest point of crystallinity before melting. 
 
Attenuated Total Reflectance Infrared Spectroscopy (ATR-IR) allowed observation of 
reversible band shifts assigned to the formation of hydrogen bond networks with water that were 
observed after only 5 minutes at 30 °C. Under heating, the band at 1110 cm-1 shifted at 55.9 °C, 
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verifying the DSC characterization gelation scheme. High-set gels were produced at 95 °C with 
less than 10% reversibility possible as monitored by the ratio of the peaks at 1080 and 1045 cm-1 
with low-set gels showing much more reversibility45. 
Rheological studies measuring the storage modulus of Curdlan gels throughout the 
gelling temperature range demonstrated that there is an initial increase in storage modulus before 
the low-set gel temperature as single helices aggregate followed by a decrease as these helices 
break hydrogen bonds and then a gradual increase as the helices re-organize to form more 
crystalline triple helical structures41. This result confirms the initial breaking of bonds observed 
in the formation of the low-set gel46. 
NMR Relaxometry studies further confirm this result by measuring chain mobility during 
temperature ramping, showing a characteristic decrease in chain mobility as the single helices 
aggregate, followed by an increase as they melt, and a decrease as triple helix crystals are 
formed. It was also demonstrated was that holding temperature in the gelation regime initiated an 
annealing of triple helix crystals with the implication that discrete low-set and high-set gels are 
perhaps a misleading terminology as a continuum of states exists41.  
AFM studies have been carried out on both Curdlan and branched 1,3-β-glucans, 
allowing the observation of fiber dimensions50, 52. Three nanometer thick fibers were observed 
for Curdlan that formed network structures of fibers on mica from 0.01 M NaOH suspensions 
(Fig 8: Left). Variation of the height confirmed the heterogeneity of Curdlan at this lower 
alkaline concentration. Higher concentrations of alkali (1 M NaOH) demonstrated the thickness 
of fibers falling to 0.5 nm in some places but the network structure was still intact in places, 
suggesting incomplete solubility even at high concentrations of NaOH (Fig 8; Left). The 
observation of network structures even at high alkaline concentrations suggested that the thermal 
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gelation mechanism involved partial breaking off of random coils from parent fibers that form 
triple helices to cross-link the parent fibers (Fig 8; Middle, Right). The previously observed 
increase in hydrogen bonding followed by bond breakage before triple helix assembly suggests 
that collapsed random coils might form intramolecular hydrogen bonds to single helices that then 
associate with other single helices, break intra-structural hydrogen bonds, and then reform inter-
strand hydrogen bonds to create triple helical structures. Hydrophobic interactions then also play 
a key role in holding the triple helices together 50. 
 
 
Figure 8. Atomic Force Microscopy Scans of Curdlan Gelation50. (Left) Residual network 
structure in 1M NaOH solution. (Middle) 0.1 M NaOH suspension of Curdlan that was heated at 
90 °C for 4 hours. (Right) Bulk-gel precursor from the same suspension demonstrating the 
formation of densely cross-linked networks. 
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Curdlan has been investigated with Single Molecule Force Spectroscopy (SMFS) to 
elucidate the transitions that occur during increased concentrations of sodium hydroxide. 
Experimentation on 0.5 M NaOH solutions of Curdlan demonstrated the stretching of single 
Curdlan chains, indicative of random coils of Curdlan in alkaline solutions of this concentration.  
A helix-coil transition was observed in 0.1 M NaOH with a 60 pN force proposed to be required 
to begin the unwinding of triple helical structures. At 0.2 M NaOH, it was believed that the 
observed phenomenon was the unwinding of single helices from duplex structures, as the 
unwinding force was only 40 pN. This transition from triple helices to single helices and then 
random coils from 0.19-0.24 M NaOH agreed well with prior predictions and elucidated a 
possible intermediate duplex state between triple helix and random coil that may be involved in 
gelation51. 
Despite the extent of characterization efforts, the exact mechanism for gel formation of 
Curdlan is disputed. Some harmony is materializing out of the use of more visual techniques 
such as AFM, explaining some of the otherwise strange bond breakages and formations observed 
via rheology and NMR studies. Despite this, AFM studies have introduced confusion of their 
own by showing the presence of random coil networks even at very high alkaline concentrations. 
The possible mechanism of cross-linking of these fibers by the increasing populations of single 
and triple helices to create Curdlan gels is a promising lead. It is the prevalence of complex 
mixtures of random coils, single helices, and triple helices at different alkaline concentrations 
and temperatures that have made the elucidation of the mechanism of Curdlan gelation a moving 
target as characterization techniques improve to gain a better understanding of these populations. 
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2.2 Bioactivity of 1,3-β-glucans 
The interaction of 1,3-β-glucans with immune cells generates a potent pro-inflammatory 
effect consisting of stimulation of the production of cytokines, increased phagocyte and 
lymphocyte proliferation, oxidative burst, and phagocytosis against opsonized tissues. This pro-
inflammatory effect has led to a number of therapeutic applications using 1,3-β-glucans to impart 
tumor inhibition, disease resistance, and wound healing. These processes are caused by a number 
of different initiating pathways. 
2.2.1 Activation of Alternative Complement Pathway 
Zymosan, a fraction of sterilized cell wall from Saccharomyces cerevisiae containing 
70% β-glucans, was known to be an initiator of the alternative complement pathway since the 
discovery of the properdin pathway in 1954, forming an active complex with properdin that 
allowed the consumption of C3b, complement cascade, and the destruction of the pathogen53. 
Interaction with C3b initiates the formation of membrane attack complex (MAC) and the 
generation of opsonins among many other processes. Kinetic studies on the formation of 
zymosan-properdin complexes were carried out and the involvement of factor B in the process of 
C3 and C5 consumption was demonstrated54. Later, it was verified that there neutral 1,3-β-
glucans could yield a prominent activation of the alternative complement pathway, ruling out the 
hypothesis that zymosan activation occurred due to the presence of phosphate groups in the 
unpurified fraction55.  
2.2.2 Interaction of 1,3-β-glucans with Phagocytes and Lymphocytes 
The antitumor activity of zymosan was originally believed to be due to a lipid fraction 
until it was demonstrated that isolated polysaccharide fractions of zymosan decreased the half-
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life of colloidal carbon 10 times when administered to mice by generating hyperplasia and 
hyperfunction in immune cells56. The cellular membrane receptor on phagocytic macrophages 
for the binding of 1,3-β-glucans was the focus of a large volume of research with the candidates 
being a complement receptor or Dectin-1, both of which were found to be dependent on iC3b 
opsonization, the proteolytically deactivated form of the complement protein C3b. It was 
demonstrated in 1986 that Complement Receptor 3 (CR3) was responsible for the binding of 
opsonized zymosan57. In 1996, it was demonstrated that macrophages bearing CR3 were capable 
of attacking any iC3b-opsonized pathogen in the presence of 1,3-β-glucans58. The complement 
protein C3b normally coats pathogens marking them for detection by Complement Receptor 1 
(CR1) or activation of complement cascade. The deactivation of C3b to iC3b is a regulatory 
mechanism to avoid unnecessary immune activity. Since iC3b is recognized by CR3 in the 
presence of 1,3-β-glucans, CR3 and the iC3b opsonin play a critical role in innate immunity 
towards fungal and microbial pathogens, mediated by the presence of 1,3-β-glucans in these 
pathogens. Independently delivered 1,3-β-glucan could then yield a targeting of cancer cells with 
surface coatings of iC3b58.  
Using murine models, the role of CR3 and Dectin-1 were compared for the binding of 
unopsonized zymosan. It was demonstrated using fluorescent labeling that CR3 deficiency was 
inconsequential in murine models59. Further evidence for this result was provided in 2003 where 
the production of a cytokine, Tumor Necrosis Factor Alpha (TNF-α), was used as a measure of 
receptor efficacy when macrophages were retrovirally transduced to produce large amounts 
Dectin-1. The transduced macrophages bound more unopsonized zymosan and showed a dose 
dependent secretion of TNF-α60.  
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In the most recent studies with human neutrophils, no phagocytosis of unopsonized 
zymosan was observed when CR3 was blocked, no zymosan binding was possible in CR3 
deficient humans, and the efficacy of respiratory burst was inconsequential with Dectin-1 primed 
zymosan compared to plain zymosan. It was concluded that although Dectin-1 plays an essential 
role in mediating the interaction of 1,3-β-glucans with immune cells in murine models, 
functional CR3 was required for the efficient binding and response to both opsonized and 
unopsonized zymosan in humans61. Figure 9 shows two critical elements to the structure of CR3, 
the β-Chain that interacts with a 1,3-β-glucan and the α-Chain that interacts with an iC3b 
opsonin. The binding of 1,3-β-glucans to the β-chain initiates cell stimulation as well as a 
conformational shift in the α-Chain that allows CR3 to bind iC3b-opsonized pathogens (Fig 
10)62.  
Although most studies focus on the binding of 1,3-β-glucans to CR3 or Dectin-1 on 
phagocytes, the primary form of activity of many 1,3-β-glucans such as lentinan is interaction 
with and stimulation of T-cell and natural killer cell activity to promote acquired immune 
response and lysis by other means such as the release of perforins and granzymes. Lentinan also 
interacts with T-cells and natural killer cells to promote proliferation of the cells themselves or 
proliferation with desirable IL-2 cytokine receptors63, 64. Very recently, increases in lymphocyte 
proliferation were observed as a result of all 1,3-β-glucan treatments with Curdlan at 
concentrations up to 800 ug/mL yielding the greatest effect65. Thus more research into the effects 




Figure 9. Schematic of the Domains of Complement Receptor 362. Complement Receptor 3 
consists of the β-chain which interacts with 1,3-β-glucans and the α chain that experiences a 
conformation shift, allowing the recognition of iC3b opsonins. 
 
Figure 10. β-Glucans Initiate a Conformational Shift to Allow Response to iC3b Opsonin62. 
Under normal circumstances, CR3 dual interactions with 1,3-β-glucans and iC3b allow for the 
recognition of fungal pathogens but this system has been leveraged for cancer therapy. 
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2.2.3 Pharmacological Effects of 1,3-β-glucans 
1,3-β-glucans stimulate the production or induction of a variety of pro-inflammatory 
mediators and cytokines including TNF-α, Interferon- γ (IFN-γ), Granulocyte-Macrophage 
Colony Stimulating Factor (GM-CSF)66, Inducible Nitric Oxide Synthase (iNOS), Macrophage 
Inflammatory Protein 2 (MIP-2), and a host of Interleukins (IL-1Iβ, L-8, IL-10, IL-12, IL-4, 
IL6)65. This stimulation was demonstrated to occur at the mRNA level with MIP-2 and TNF-α 
similar to lipopolysaccharide (LPS) stimulation67, 68. The production of these pro-inflammatory 
mediators is linked to activation of Nuclear Factor- κB (NF- κB). A recent study has highlighted 
the critical role of a phospholipase C enzyme and a Calcium ion flux in the intracellular signaling 
resulting from receptor activation69.  
Oxidative burst is an innate immune response to pathogens external to or internalized by 
phagocytes that is characterized by the release of reactive oxygen species (ROS). Different types 
of ROS include peroxides and peroxynitrites formed from superoxide anions and nitric oxide that 
are responsible for peroxidation of lipids and proteins and the cytotoxicity of microbes. Curdlan 
was shown to effectively mediate the induction of iNOS and production of nitric oxide in vitro in 
rat macrophages67. Very recently, a variety of 1,3-β-glucans were shown to stimulate the 
production of ROS in differing amounts dependent on branching and chain length65.  
Phagocytosis of pathogens or opsonized pathogens in response to 1,3-β-glucan 
stimulation has been studied much less than the corresponding oxidative burst and cytokine 
producing pharmacological effects in the recent literature. However, good theories exist as to the 
mechanism of this behavior62. An in vitro phagocytosis test using synthetic microbeads was 
recently formulated, serving as an excellent starting point for the comparison of different 1,3-β-
glucan structures70. Elimination of pathogens or cancer cells can also occurs by acquired cellular 
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immune pathways involving cytotoxic T-cells or natural killer cells as was initially demonstrated 
with lentinan63 and later demonstrated with most 1,3-β-glucans65. 
The pharmacological effects of 1,3-β-glucans are heavily dependent on the specific 
conformation and structure of the polysaccharide. When studying macrophage activation by 1,3-
β-glucans in vitro, macrophage activation was observed with the addition of 10-100 ug/mL and 
enhanced by pre-treatment with sodium hydroxide, dimethylsulfoxide, or zymolase to release 
free glucans from the particulate systems. Since treatment with sodium hydroxide or 
dimethylsulfoxide causes the production or single helices and random coils from more crystalline 
arrangements, it was concluded that the single helix was the most potent conformation for 
macrophage activation.  In addition, longer 1,3-β-glucans were found to be necessary as shorter 
laminaroligosaccharides showed much less activity68. These findings were consistent with early 
results suggesting that the single helix was critical43, 71 and that shorter 1,3-β-glucans could not 
produce iC3b recognition in CR358. In the most recent studies, these effects along with the 
effects of branching continue to be investigated72. Despite the fact that the removal of branching 
was the only way to generate an immunomodulatory response from pachyman18, other studies 
suggest that a complex branching structure in fungal 1,3-β-glucans may be more effective20. No 
firm conclusion yet exists in the literature pointing to the most potent conformation and structure 
of a 1,3-β-glucan for therapeutic usage but it is generally accepted that the single helix is critical 
and higher molecular weight polysaccharides are superior. 
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2.3 Pharmacological Applications of 1,3-β-glucans 
2.3.1 Cancer Inhibition 
In combination with radiotherapy and/or chemotherapy, the 1,3-β-glucan, lentinan, has 
been used for cancer immunotherapy in Japan since 1986 for the treatment of lung, gastric, and 
cervical cancers31. In the early studies on lentinan with subcutaneous implantation of sarcoma 
180 into mice, intraperitoneal injection of 1-4 mg/kg of lentinan over 10 days yielded a tumor 
inhibition of 99.6% and inhibition ratios of 96% were also found with pachymaran, the 
synthetically de-branched form of pacyhman18. A number of theories on the nature of the 
antitumor effects have arisen in the literature. The effects of lentinan and pachymaran are 
thought to rely heavily on T-lymphocytes as the removal of the thymus or treatment of mice with 
antilymphocyte serum (ALS) virtually eliminated antitumor effects63. This was verified in 1992 
when lentinan was found to increase natural killer cell activity and the proliferation of T-cells 
with IL-2 receptors64. Experiments with bovine serum albumin (BSA) showed that denaturation 
of protein helices could be linked to the antitumor mechanism of lentinan as only those 
polysaccharides that denatured the protein showed antitumor activity73. The generation of new 
serum proteins was also thought to be linked to the T-cell mediated effects of lentinan74. 1,3-β-
glucan derivatives such as pachyman, pachymaran, and corresponding derivatives have been 
found to activate the alternative pathway of complement, involving factor B, as opposed to the 
T-cell mediated route55.  
Throughout the literature, other 1,3-β-glucans showing similar effects against solid 
sarcoma 180 were discovered. In the early studies in the 1970’s, scleroglucan was found to 
produce inhibition ratios of 90.4% at a dose of 2.5 mg/kg and Curdlan was found to inhibit 
tumors from 99-100% with doses ranging from 10-20 mg/kg19. In 1985, a branched 1,3-β-glucan, 
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grifolan, was found to inhibit solid sarcoma 180 up to 97.9% 75. In 2001, a complex branched 
1,3-β-glucan from Agaricus Blazei was found to inhibit up to 99.3% of tumor growth20. The 
robust antitumor effects of various 1,3-β-glucans have lead to the modern use of 1,3-β-glucans as 
adjuvants to monoclonal antibody treatments. Human tumor xenografts from melanoma, 
epidermoid carcinoma, breast carcinoma, metastatic lymphoma, and daudi lymphoma were 
affected positively by combination treatments of 1,3-β-glucans and antibodies yielding tumor 
inhibition and survival rates greater than individual treatments76. A recent review considers the 
topic of combined treatments for cancer immunotherapy in more detail32. 
To improve the usability of 1,3-β-glucans, a significant amount of work has gone into the 
development of water-soluble derivatives that retain antitumor efficacy. Early work with the 
development of water-soluble carboxymethylpachymaran showed tumor inhibition ratios up to 
99.6% in solid sarcoma 180 with doses of 5 mg/kg, equal with lentinan. Interestingly, the use of 
the water-soluble derivative allowed for the use of other injection routes besides intraperitoneal 
injection to obtain the same result77. Other 1,3-β-glucans including hydroxymethylpachyman and 
hydroxypropylpachyman showed up to 100% inhibition at 5 mg/kg in solid sarcoma 18077. In 
1979, various water-soluble carboxymethylglucans were synthesized that also showed high 
antitumor activity78. Carboxymethyl Curdlan in particular is used extensively in modern 
applications. Water-soluble glucosyl, sulfoethylated, and sulfopropylated Curdlan derivatives 
also retain antitumor activity79, 80. All of these results suggest that solubility of the 1,3-β-glucan 
is not a critical factor for antitumor activity. 
2.3.2 Infection Resistance 
Since 1,3-β-glucans cause cytokine production, oxidative burst, immune cell 
proliferation, and increases in phagocyte and lymphocyte activity, 1,3-β-glucans have been 
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investigated for use in increasing overall host immunocompetency. In 1978, It was demonstrated 
that mouse survival rates for immune challenge with staphylococcal infection increased 
dramatically with 3% mortality observed in 1,3-β-glucan treated mice vs. 30% in the control 
group81. More recently, oral administration of 1,3-β-glucans to promote resistance to fungal and 
bacterial infection has been attempted with a full pharmacokinetic characterization. It was 
demonstrated that the administration of glucan phosphate, laminarin, and scleroglucan through 
oral ingestion may be advantageous for obtaining a sustained absorption from the gastrointestinal 
tract, that hepatic clearance of 1,3-β-glucans was ineffective, and that different 1,3-β-glucans had 
different absorption profiles with laminarin and scleroglucan showing biphasic plasma 
absorption. Oral administration led to the secretion of interleukins, an increased expression of 
Dectin-1 on macrophages, and an increased expression of Toll-Like Receptor 2 on dendritic 
cells. As a result, survival rate for Staphylococcus aureus bacterial and Candida albicans fungal 
challenge increased 50% in mice through oral administration22. 
This ability to impart infection resistance has been of growing interest with a growing 
volume of work attempting to increase immunocompetency in fish and pigs. In 1991, Curdlan, 
inulin, krestin, laminarin, lentinan, schizophyllan, scleroglucan, yeast glucan, and zymosan were 
tested to investigate an improvement in bacterial resistance for Cyprinus Carpio L. Carp against 
Edwardsiella tarda bacteria. At a dose of 10 mg/kg, schizophyllan had a 60-80% survival rate 
and lentinan and scleroglucan had 55-75% survival rate on day three vs. complete mortality in 
control groups. When challenged with Aeromonas. hydrophila, survival rate was 70% for 
lentinan, 80% for scleroglucan, and 60% for schizophyllan when treated with 5 mg/kg after 5 
days vs. complete mortality in control groups21. A later study found similar results with tilapia 
and grass carp towards infection with Aeromonas Hydrophila82. Resistance to infection with 
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Streptococcus suis bacteria in weaning pigs was negative in 199583 but more recently, increased 
levels of TNF-α were observed in weaning pigs and an interesting synergistic effect with vitamin 
C supplements was postulated84. In addition, a positive resistance to LPS challenge was 
observed85. The most recent in vivo studies showed a resistance to intestinal colonization by 
Enterotoxigenic Escherichia coli (ETEC), fewer bacteria in faeces, and less severe diarrhea86. 
Recent in vitro studies confirm the stimulating capacity of a variety of 1,3-β-glucans, 
demonstrating that porcine leukocytes show increased cytokine and ROS production and 
increased proliferation in response to 1,3-β-glucans65. It is now clear that the differences in 
results obtained over >20 years of research into improving resistance to infection in various 
species are highly dependent on the specific 1,3-β-glucans used, their concentration, and their 
conformation during administration. 
2.3.3 Viral Resistance 
Similar to work in resistance to bacterial and fungal challenge, sulfated 1,3-β-glucans 
have been tested for the ability to impart resistance to viral infection to malaria, herpes simplex 
virus (HSV) 87, 88, and HIV. In early studies, Curdlan sulfate completely inhibited HIV virus 
infection in MT-4 cells at 3.3 ug/mL as characterized by the lack of virus specific antigens89. 
These results were consistently verified90-92, leading to ongoing clinical trials. Malaria infection 
was resisted in the presence of Curdlan sulfate in vitro through an inhibited fusion mechanism87. 
More recently, sulfated 1,3-β-glucans have imparted resistance to infection by HSV through a 
suggested electrostatic binding to the viral surface that inhibits interaction with host cells88. This 
mechanism of viral interaction was studied with experiments between Curdlan sulfate and 
polylysine, causing the formation of electrostatic cross-linking to produce clear, strong gels. It 
was believed that this electrostatic interaction between anionic Curdlan Sulfate and cationic 
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polylysine may mimic an interaction between Curdlan sulfate and a cationic glycoprotein 
(gp120) in the viral envelope of HIV, blocking interactions with CD4 receptors93. This blocking 
mechanism has been extensively studied in experiments on HIV inhibition94-96.  
In 1994 it was confirmed that Curdlan sulfate interacts with gp120 on HIV-1 that affects 
the cell-virus fusion mechanism but that there was no interaction between Curdlan sulfate and 
CD4 because pretreated cells were vulnerable to infection. This blocking mechanism was 
supported by evidence suggesting inhibitory action before any viral genetic replication94, 95. This 
result was later confirmed with additional evidence that Curdlan sulfate inhibits TNF-α 
production that led to T-cell apoptosis caused by gp120 interaction with CD492. An additional 
mechanism may lie in the mediation of β-chemokines and cytokines by Curdlan sulfate, with 
demonstrations that MIP-1α, MIP-1β, and MCP-1 were all inhibited whereas RANTES and IL-
16, two cytokines known to have anti-HIV activity, were enhanced97. 
The synthesis of Curdlan sulfates in varying conformations and their incorporation into 
other systems have received attention as well98. Azidothymidine (AZT), a nucleoside analogue 
that inhibits viral reverse transcriptase has been chemically bonded to Curdlan sulfate with the 
hope of using the tendency of Curdlan sulfate to concentrate in the lymph nodes and bone 
marrow to deliver drugs to the RES, using Curdlan sulfate as an HIV inhibitor and drug delivery 
vehicle. A hydrophobic alkylene group was used a spacer between the two components that 
would be susceptible to enzymatic hydrolysis. The overall drug delivery system demonstrated 
the enzymatically-triggered release of AZT89, 99. An additional opportunity follows the recent 
research around fullerene derivatives as anti-HIV agents100. Water-soluble Curdlan Sulfate-C60 
conjugates have been synthesized that combine the anti-HIV activity of Curdlan sulfate and 
fullerenes101. Alongside new conjugates and delivery vehicles, research is also working on 
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improving the synthesis of Curdlan sulfates. A growing amount of work exists on the 
development of easy functionalization mechanisms by ‘Click Chemistry’ 102-104. Some of the 
most recent work has investigated the use of ultransonication for sulfation of Curdlan with 
impressive results showing four-fold increases in the degree of substitution. However, molecular 
weights were decreased significantly105. 
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2.3.4 Wound Healing 
Wound healing effects of 1,3-β-glucans have been studied extensively as a growing 
application. Suggested effects of 1,3-β-glucans related to wound healing are improved transport 
of macrophages to the wound site106 and improved collagen deposition24. The effect on collagen 
deposition was originally thought to be indirect through the stimulated release of growth factors 
from macrophages but a recent study has shown that insoluble glucan from zymosan, laminarin, 
and glucan phosphate can interact, sometimes only partially, with Normal Human Dermal 
Fibroblasts (NHDF). This binding stimulated NF- κB activity and IL-6 mRNA expression107. 
The discovery of increases in NF- κB activity and direct binding to NHDF’s has stimulated 
investigation into the ability of 1,3-β-glucans to induce collagen synthesis. Type I and III 
collagen biosynthesis was substantially improved with treatment with 1,3-β-glucans in recent 
studies by measurement of pro-collagen mRNA and hydroxyproline levels96. Consistent with 
these findings, Beta-glucan Collagen Matrix (BGC) was evaluated in the treatment of pediatric 
burns with observed reduction in pain and required analgesic, reduction in the necessary number 
of wound dressing changes, and improvements in healing and cosmetic appearance108. 
 33 
2.4 Structural Applications of 1,3-β-glucans 
The ability of 1,3-β-glucans to form helical structures that can be gelled with the 
application of heat and humidity has generated a fast growing volume of research on the use of 
these polysaccharides as structural agents to provide scaffolding for the formation of 
macroscopic and  nanoscale structures. 
2.4.1 Food Gels 
The gelation mechanism of Curdlan has been heavily utilized in food science after the 
U.S Food and Drug Administration (FDA) approved Curdlan for addition to food in 199629, 30. 
Curdlan gels have been used in improving food stability through freezing and thawing cycles29, 
109, reducing fat content in deep-fat frying applications30, 110, creating fat mimetic systems111, 112, 
and encapsulation and release of pH sensitive pigments113.  
Nakao investigated the gel strength and syneresis of Curdlan gels at room temperature 
and when frozen and formed into strawberry and honey flavored gels, soy milk noodle-like gels, 
and mixtures with other gelling agents. Gels were subjected to thermo-irreversible gelling 
temperatures of 100-130 °C and the gel strength was observed to continually increase as heating 
was applied. Syneresis, as measured by absorbing water from the gel and measuring mass after 
20 hours of refrigeration, increased with gelling temperature and decreased with concentration. 
Freezing and thawing increased syneresis but Curdlan gels had higher gel strength after thawing 
than carrageenan, agar-agar, and konjac. The addition of waxy corn starch and sucrose reduced 
syneresis. The creation of thin-layered Curdlan gels containing various flavoring agents to 
replace condiments and tofu noodles stabilized with Curdlan rather than coagulation of soy milk 
with calcium sulfate have been proposed29. Combinations of Curdlan, Xanthan, Locust Bean 
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Gum, and Guar Gum have also been evaluated for freeze-thaw stability with Curdlan and 
xanthan hydrogel complexes found to be the most stable in terms of viscosity, heat stability, and 
gel strength109. 
Curdlan has been investigated as an additive to reduce fat content. The ability of Curdlan 
to act as an oil barrier and repel fat in frying applications and its effects on the physical 
properties of donuts was investigated. The addition of 1% of Curdlan to the donut batter resulted 
in a reduction of 5.6% in total fat content and 9% in oil uptake during frying. Curdlan was also 
found to inhibit moisture loss30. This research has also been expanded to the frying of other 
products, namely akara from cowpea flour (52). Curdlan reduced fat content by 10% in akara 
with mixtures of 1% Curdlan and 20% soybean flour while maintaining texture as long as the 
composite flour was sufficiently moisturized prior to use110. 
Curdlan has been investigated as a fat substitute in low-fat meat products with ‘false-fat’ 
created from a mixture of 3% Curdlan, 10% microcrystalline cellulose, and 1% modified tapioca 
starch. The ‘false-fat’ was incorporated into sausages (20%) and compared to sausages made of 
20% pork fat. The mixture was comparable to natural pork fat in terms of lubricity, viscosity, 
mouth feel, and appearance as determined by static viscoelasticity measurements112. Curdlan was 
also added to minced pork as a gelation agent where it was found to form an irreversible gel that 
retained moisture111. 
The isolation of environmentally sensitive pigments has been an important issue in food 
science. Curdlan has been used to encapsulate and release pH sensitive blackberry anthocyanins. 
Spraying of a suspension of ~5% Curdlan and anthocyanin extract into a soybean oil bath and 
recovering capsules by filtration proved an effective means to stabilize the dye113.  
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2.4.2 Environmental Gels 
Removal of contaminants from water sources is a critical issue in today’s society. Heavy 
metal removal from water is often carried out with activated carbon particles that contain porous 
internal structures capable of adsorbing metal contaminants. Application of activated carbon was 
facilitated by suspending particles in Curdlan gels demonstrating the removal of copper, 
manganese, lead, and cadmium from oriental herbs with the pore size adjustable based on 
Curdlan/Carbon ratio114. This preliminary research could be extended to water purification. 
The removal of Dense Non-Aqueous Phase Liquids (DNAPL) from aquifers was 
addressed with a Curdlan gel based treatment. Dual columns, one containing coarse sand and the 
other fine sand were set-up in temperature controllers to simulate temperature fluctuations in 
Alaskan environments. The two columns were meant to mimic high permeability and low 
permeability paths of DNAPL during conventional removal techniques. Alkaline solutions (0.01 
N NaOH) of Curdlan were added into the coarse sand column, gelling due to the natural acidity 
of the soil (gelation by neutralization) and restricting flow through the coarse sand column and 
concentrating DNAPL in the fine sand column. This demonstration of the modification of soil 
permeability by Curdlan gels was promising for the development of new strategies to remove 
DNAPL from aquifers115.   
2.4.3 Nanostructure Formation 
The helix forming capability of 1,3-β-glucan is attractive for nanoscience applications 
where structures with dimensions or conformations suitable to interact with single helices are 
manipulated. The triple helical structures of Curdlan and schizophyllan have been used to 
encapsulate Single Walled Carbon Nanotubes (SWCNT) that were otherwise insoluble in water. 
Re-naturing of Curdlan and schizophyllan from a DMSO solution (by addition of water) caused 
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encapsulation of SWCNTs as observed as helical oblique stripes on the surface of SWCNT 
bundles through AFM (Fig. 11). This coating was believed to stabilize SWCNTs, avoiding 
aggregation and improving solubility116.  Hierarchical superstructures have been assembled using 
these stabilized one-dimensional carbon nanotubes, utilizing ammonium and sulfite 
functionalized Curdlan backbones to first encapsulate SWCNT’s and then stack the nanotubes 
into layers via alternating electrostatic interactions 117. The structures formed may have utility in 
both SWCNT structure formation and the hierarchical assembly of bio-active polymers such as 
peptides or nucleotides. 
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Figure 11. Helical Encapsulation of SWCNT’s as seen through AFM116. (A) SWCNT’s, (B) 
Schizophyllan encapsulation, (C) Curdlan encapsulation, (D) Magnified view of Schizophyllan 
encapsulation showing helical oblique striations. 
 
 
Figure 12. Conical-terraced assemblies of Laminarin as seen through AFM118. (A) AFM 
height image, (B) AFM amplitude image, (C) 3D construction from AFM, (D) Cross-sectional 
height showing the presence of a pore in the center. 
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The formation of ordered metal nanowires for application in nanoelectronic circuitry has 
been an ongoing challenge in nanotechnology. Historically these nanowires have been 
constructed using surfactant assemblies or porous nanostructures to direct growth but recently 
there has been interest in schizophyllan as a scaffold or templating material for Au nanowires. 
Mixing Au nanoparticles in water and schizophyllan in DMSO allowed the precipitation of 
schizophyllan helices containing 1D arrangements of Au nanoparticles. After washing and 
chemical reduction, photo-induced dissociation, or a combination of both, the helical structure 
contained ordered arrangements of discontinuous Au nanowires119. This finding could be used to 
create helical micelles containing any sort of nanoparticle including those designed to deliver 
therapeutic substances, creating functional hierarchical assemblies. The templating effects of 
schizophyllan have been used in the development of a number of other systems as well including 
silica120, oligosilane 36 and porphyrin nanofibers35, and in situ polymerizations121. Other 1,3-β-
glucan are also currently under investigation for the templating and scaffolding properties 
including laminarin which has recently been formed into terraced cone-like structures (Fig 
12)118. These advancements in templating technologies utilizing 1,3-β-glucans provide a more 
practical and cost effective method to scaffold nanostructures than DNA templating and provide 
important pharmacological properties in the process. 
 In addition to nanostructure templating 1,3-β-glucans are currently being used chemically 
in nanoparticle synthesis. Carboxymethyl Curdlan was used a ‘green’ biopolymer reducing agent 
in the synthesis of silver nanoparticles. Light scattering and TEM demonstrated that 40-80 nm 
particles were formed within 10-15 minutes by reduction of silver ions in CM-Curdlan 
solution122. 
 39 
2.4.4 Liquid Crystals 
The ability for 1,3-β-glucans to gel when dialyzed against calcium chloride solution has 
been utilized to create liquid crystalline gels with interesting refractive index gradients and other 
optical properties. A stepwise gradient of crystalline order from the outside towards the 
amorphous center was observed for gelation of a Curdlan alkaline solution against calcium 
chloride wherein the calcium ions cross-link hydroxyls at the C(6) position. The transition from 
the random coil conformation in alkaline solution to triple helix in the calcium chloride solution 
is responsible for this effect as a competition occurs between the states before they cross-link123. 
This system has been studied in terms of the effects of Curdlan molecular weight124 and used as a 
model in the liquid crystal gelation of DNA125, 125. Using creative experimental setups, these 
liquid crystalline gels have been developed in the form of polymer beads as well, opening up 
application in oral drug delivery126. 
2.5 Drug Delivery Applications of 1,3-β-glucans 
2.5.1 Drug Impregnated Gels 
Gel encapsulation of indomethacin, prednisolone, and salbutamol sulfate in Curdlan gel 
suppositories has been the hallmark example of Curdlan application in this area. Curdlan 
suppositories with intended application in rectal administration have been developed wherein 
Curdlan gels would allow drug diffusion in the lower rectum, avoiding first pass clearance in the 
liver. The proposed systems an improvement over other suppository systems that immediately 
dissolve and deliver drug into the colon and consequently the hepatic portal vein. Diffusion 
controlled release of indomethacin was possible with Curdlan suppositories wherein the release 
rate was unaffected by hypotonicity or isotonicity127. Dry tablet encapsulation of theophylline by 
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spray drying Curdlan/Theophylline solutions were also demonstrated with good 
pharmacokinetics128.  
2.5.2 Nanoparticle Drug Delivery 
Nanoparticle drug delivery approaches have been successful with the synthesis of solid 
lipid nanoparticles consisting of cacao butter and Curdlan. Curdlan was believed to coat cacao 
butter nanoparticles when introduced in an ammonium hydroxide solution. The stabilized 
nanoparticles were loaded with verapamil, which was quickly released within 12 hours due to its 
high solubility in the lipid core129. Solid lipid nanoparticles consisting of glyceryl caprate coated 
with Curdlan encapsulating doxorubicin have also been developed with encapsulation yields of 
2.8%, particle size less than 200 nm, and stability after one year of frozen storage130. 
Amphiphilic copolymers self assemble to form micellar structures applicable to drug 
delivery due to their drug loading capability and small size, taking advantage of the enhanced 
permeability and retention effect2, 3. Carboxymethylated Curdlan (CM-Curdlan) has been 
conjugated to sulfonylurea to create a grafted polymer with a hydrophillic backbone and 
hydrophobic sulfonylurea branches. All-trans Retinoic Acid (ATRA) was delivered from 
hydrogel nanoparticles to a hepatoma cell line by modification with lactobionic acid on the 
backbone of CM-Curdlan. Sonication was used to induce nanoparticle formation from water with 
drug loaded particle sizes of 181 nm. High encapsulation efficiencies and up to 50% drug release 
as studied by dialysis in saline was possible with first order release kinetics33. Curdlan 
copolymers have been developed with the conjugation of CM-Curdlan to cholesterol in order to 
encapsulate epirubicin via amphiphilic copolymer self-assembly initiated by probe sonication. A 
broader distribution in cells over the bare epirubicin was observed with no cytotoxicity131.  
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2.5.3 Polynucleotide Complexes 
In the last ten years, the development of polysaccharide-polynucleotide complexes has 
been of growing interest and especially so with 1,3-β-glucans that form hydrogen-bonded helical 
structures similar to the hydrogen bonds formed by polynucleotide chains in DNA. Nanoscale 
complexes formed between soluble 1,3-β-glucans and polynucleotides could be used 
therapeutically to provide a potent polynucleotide delivery system that also bears the 
pharmacological properties of 1,3-β-glucans. In 2000, using dextran, pullulan, and amylose with 
poly(C) caused no association as measured by circular dichroism spectra but lentinan and 
schizophyllan, water soluble 1,3-β-glucans showed a drastic change indicative of the formation 
of a complex. Insoluble 1,3-β-glucans such as Curdlan could not be used as they precipitated 
before any nanoscale complex could form132. Shortly after this finding with Curdlan, the 
polynucleotide complex was successfully formed by first carrying out a hydrolytic cleavage of 
the backbone to reduce the molecular weight133. More recently, the addition of solubilizing 
carbohydrate appendages through click chemistry to Curdlan has been an alternative route in 
utilizing Curdlan to bind poly(C)134. Using a similar chemical scheme, a positive ammonium 
group was grafted onto Curdlan to render it water soluble and capable to include a 
polynucleotide. In this instance, electrostatic interactions with the guest macromolecule were 
thought to assist the complexation135. The formation of the Curdlan-poly(C) complex was 
studied through semi-empirical molecular orbital calculations, demonstrating the presence of 
new hydrogen bonds between the host and guest and a unique deformation of the ribose sugar in 
the polynucleotide34. In addition, it has also now been demonstrated that the parallel arrangement 
of the two macromolecule chains in the complex is favoured136. Most of the work in this area has 
utilized homogeneous polynucleotides, as this has been found to be the only type of 
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polynucleotide capable of forming helical complexes. Recent work has generated the first 
potential applications of these findings with the development of a homogenous polynucleotide-
appended anti-sense oligonucleotide to which a poly(ethylene glycol) (PEG) grafted 
schizophyllan copolymer could bind in a helical complex. The PEG grafts improved cellular 
uptake and reduced lysosomal degradation, allowing for successful demonstration of inhibited 
cell-growth through polynucleotide delivery137, 138. 
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2.6 Future Research 
1,3-β-glucans have enormous potential in a wide variety of fields due to their unique 
helix and gel forming capacity and potent pharmacological properties. As the literature 
simultaneously characterized the pharmacological effects and discovered the helical 
arrangements formed by these polysaccharides, two streams of research could be clearly 
identified: the first being the discovery of potential use of these polysaccharides in direct 
immunotherapeutic intervention for the treatment of cancers, healing of wounds, and impartation 
of microbial, fungal, and viral resistance and the second being the use of the helical gel structure 
beginning with the creation of food gels and now growing deeper into the development of 
nanostructures and encapsulation and release of active therapeutics. These two clearly defined 
streams will coalesce with a greater volume of research dedicated to applications such as drug 
delivery that utilize both the pharmacological and structure forming capabilities of 1,3-β-glucans.  
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3.0 Research Objectives 
 This thesis focuses on the development of improved drug delivery systems utilizing 
Curdlan. These systems differ from other polymer drug delivery systems because they bear the 
innate immunotherapeutic potential of 1,3-beta-glucans, making them multi-functional. From the 
literature, key works stand out in the history of Curdlan research such as the development of 
nanoparticle drug delivery systems33, 129, 131, research into polynucleotide inclusion complexes135, 
and the thermal gelation of Curdlan to create gel suppositories127. This thesis discusses 
significant contributions to the research on Curdlan drug delivery in both a nanoparticle form and 
as a hydrogel. 
3.1 Polymer Nanoparticle Drug Delivery Objectives 
 For the development of polymer nanoparticles, Curdlan has not yet been used to its 
fullest potential. All applications of Curdlan in nanoparticle drug delivery thus far have utilized 
Curdlan as a water-stabilizing component. For example, a cholesterol-curdlan copolymer was 
developed wherein the cholesterol is hydrophobic and the Curdlan is relatively hydrophilic, 
allowing for micellar self-assembly to nanoparticles131. Again, a sulfonyl urea and Curdlan 
conjugate was made wherein Curdlan is once again the hydrophilic component, allowing for self 
assembly33. The problem with such an approach is that it does not utilize the natural 
hydrophobicity of Curdlan, which can yield drug association, and it exposes Curdlan on the 
surface of the particles. Since Curdlan interfaces with immune cells to provide its 
immunotherapeutic action, this architecture renders particles unable to be targeted to a specific 
site of action.  To address this, a new copolymer nanoparticle platform has been developed 
where Curdlan is used as the central, hydrophobic core of the nanoparticle. Poly(ethylene glycol) 
(PEG) is used as the water stabilizing component of the copolymer. Doxorubicin, a hydrophobic, 
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chemotherapeutic drug is used as the model drug for the platform. This work is highly significant 
as a demonstration of Curdlan as a new platform for polymer nanoparticles where both the 
internal core of the system is both an attractor for the drug payload and an immunotherapeutic 
adjuvant.  
Specific objectives for this work have been: 
1. Synthesis of Curdlan-graft-PEG. 
2. Spectroscopic validation of the new copolymer compound. 
3. Light scattering evaluation of nanoparticle forming capacity. 
4. Screening of the drug encapsulation capability. 
5. Demonstration of the release of doxorubicin. 
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3.2 Hydrogel Drug Delivery Objectives 
 Since Curdlan thermal gels have already been demonstrated as a valid means to obtain 
controlled release suppositories127 a new direction with hydrogel drug delivery systems was 
investigated using Curdlan. Curdlan has been highly successful in forming polynucleotide 
inclusion complexes with only simple chemical modification necessary to induce the formation 
of helical micelles134, 135. However, an inherent problem with these inclusion complexes is the 
fact that Curdlan only forms complexes with homogeneous polynucleotides at the molecular 
level, i.e. only one type of base nucleotide. This makes the phenomena uninteresting for gene 
delivery applications that attempt to deliver specific polynucleotide sequences. This issue has 
been partially overcome in the literature by first appending the useful polynucleotide with a 
section of homogeneous nucleotides to allow complex formation. This thesis describes an 
entirely different approach to creating Curdlan and DNA complexes, focusing on co-gelation of 
hydrogels instead of the formation of molecular complexes. The phenomena is dependent on the 
more recent discovery of the ability of Curdlan and DNA to form liquid crystalline gels 
(LCG)123, 124, 126, 139. Co-gelation allows the formation of a multi-phase LCG where the 
component Curdlan and polynucleotide partition into amorphous and crystalline phases. The 
hydrogel system is extremely flexible, being formed into different architectures across multiple 
length-scales from nanoparticles to macroscopic moldable cylinders. This provides ultimate 
flexibility in application from biologically implantable scaffolds to particulate delivery systems 
that allow the controlled release of polynucleotides. Controlled release is afforded through the 
use of a chelating agent to degrade the hydrogel structure.  
The specific objectives for this component of the work were: 
1. Develop a multi-phase LCG system using Curdlan and DNA as a macroscopic gel. 
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2. Evaluate the crystallinity of the LCG system using polarized light and the distribution of 
polynucleotides in the system. 
3. Demonstrate the scale-down of the system to form smaller particles. 
4. Evaluate the crystallinity of the scaled down system to ensure LCG behavior. 
5. Further scale down the system to the micro-/nano-scale. 
6. Evaluate the effect of processing parameters on architecture. 
7. Investigate the release of polynucleotides from the LCG. 
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4.0 Synthesis of Curdlan-graft-Poly(ethylene glycol) and Formulation of 
Doxorubicin Loaded Core-Shell Nanoparticles 
4.1 Introduction 
This section of the thesis describes the synthesis of a Curdlan and PEG graft copolymer that 
has allowed the formation of core shell nanoparticles encapsulating doxorubicin in high yield. 
PEG (Fig. 13) has been used previously in Curdlan copolymers for the purpose of increasing 
cellular uptake and reducing lysosomal degradation of Curdlan-polynucleotide complexes137, 138. 
Doxorubicin (Fig. 13) was chosen as the model drug for this drug delivery platform due to its 
high hydrophobicity and cardiotoxicity, making it a current target for nanoparticle drug 
delivery140, 141. PEG has been used extensively in nanoparticle drug delivery as it acts to improve 
nanoparticle efficacy and pharmacokinetics in vivo by modulating protein adsorption142-144. The 
grafting was carried out by a dimethylaminopyridine (DMAP) mediated 
dicyclohexylcarbodiimide (DCC) ester forming mechanism, reacting the functional hydroxyls on 
the Curdlan backbone with a terminal carboxylic acid group on PEG (Fig. 14). Nanoprecipitation 
was used to formulate nanoparticles and Nuclear Magnetic Resonance (NMR), Dynamic Light 
Scattering (DLS), Transmission Electron Microscopy (TEM), and UV-visible spectrophotometry 
were used to characterize the system. The synthesized system is significant in the development 
of Curdlan-based immunotherapeutic drug delivery systems because it is the first to utilize the 
hydrophobicity of Curdlan to yield drug encapsulation and the first to incorporate Curdlan at the 
center of a nanoparticle where its immunogenicity leading to its immunotherapeutic properties is 












Figure 13. Components of the Nanoparticle and the Proposed Architecture. (Top) The 
developed system consists of PEG (B) grafted to Curdlan (A) encapsulating doxorubicin (C). 
(Bottom) A model of the nanoparticle architecture. 
A B C 
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4.2 Experimental Methods 
4.2.1 Materials 
Raw Curdlan (~90 000 Da) was purchased from Wako Pure Chemical Industries and 
crushed with a mortar and pestle before use to aid dissolution. Monofunctional carboxylated 
PEG (~5000 Da) was purchased from NanoCS. Dicyclohexylcarbodiimide (DCC), 
dimethylaminopyridine (DMAP), and anhydrous dimethyl sulfoxide (DMSO) were purchased 
from Sigma Aldrich. All synthesis materials were used without further purification. Doxorubicin 
HCl was purchased from IntaTrade Chemicals GmbH and desalted according to the procedure 
described below. Amicon Filtration Units had a molecular weight cut-off (MWCO) of 10 000 Da 
and were purchased from Fisher Scientific. 
4.2.2 Desalting of Doxorubicin Hydrochloride 
Doxorubicin HCl was dissolved in distilled water at 4 mg/mL and 2 molar equivalents of 
triethylamine (TEA) were added and the solution vortex mixed until a color change to purple 
was observed. The solution was added to a separatory funnel and repeated portions of 
dichloromethane (DCM) were added. The bottom layer of DCM was removed and purged with 
compressed air at 50 °C. The obtained film was dissolved in DMSO at 6 mg/mL before use. The 
Doxorubicin-DMSO solution was serially diluted and tested in triplicate (300 µL each) in a 96 
well microplate on a Biotek Epoch Microplate system at 480 nm to produce an absorbance-
concentration calibration curve. 
4.2.3 Synthesis of Curdlan-graft-Poly(ethylene glycol) 
Curdlan (500 mg) was dissolved in 50 mL of stirring anhydrous DMSO under nitrogen 
bubbling for 1 hour. Simultaneously, carboxylated PEG (1 g) was dissolved in 30 mL of stirring 
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anhydrous DMSO at 60 °C under nitrogen bubbling for 20 minutes and DCC (600 mg) and 
DMAP (400 mg) were dissolved in 20 mL of stirring anhydrous DMSO under nitrogen bubbling 
for 20 minutes. DCC activated carboxylated PEG was formed by addition of the DCC/DMAP 
solution to the carboxylated PEG solution under stirring for 15 minutes. The activated 
carboxylated PEG solution was added to the Curdlan solution and stirred for 15 hours at room 
temperature. The final solution (100 mL) was added to 3.5 kDa MWCO dialysis tubing and 
dialyzed against 2 L of distilled water for 72 hours with water changed every 6-12 hours to 
remove unreacted PEG. The precipitated product was obtained by centrifugation with the water 
suspended over-grafted portion discarded. The product obtained from centrifugation was 
lyophilized overnight to remove water and washed 10 times with diethyl ether to remove DCC, 
DMAP, and dicyclohexyl urea. Residual ether was removed by desiccation to a dry powder 
consistency. 
4.2.4 Determination of Nuclear Magnetic Resonance Spectra  
All NMR Spectra were determined by dissolving 6.5 mg of polymer in 1 mL of DMSO-
d6 under stirring for 30 minutes and scanning the sample on a 300 MHz Bruker NMR 
spectrometer. 1H-NMR spectra were determined with 64 scans, 13C-NMR spectra with 10 000 
scans, and Heteronuclear Multiple Quantum Coherence (HMQC) spectra with 8 scans. 
4.2.5 Preparation of Doxorubicin Loaded Curdlan-graft-PEG Nanoparticles 
Curdlan-g-PEG was dissolved in DMSO at 7.5 mg/mL and varying volumes of polymer 
solution and 6 mg/mL Doxorubicin-DMSO solution were mixed at drug loading percentages 
(weight of doxorubicin/weight of polymer x 100) of 10, 20, and 40% each with a volume of 3.2 
mL and a final polymer concentration of 3.5 mg/mL One milliliter of each solution was added in 
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a slow drop-wise manner to 10 mL of stirring distilled water with a mild vortex. The polymer 
droplet was allowed to disperse completely before addition of the next drop. 
4.2.6 Dynamic Light Scattering 
DLS results were obtained by removing 3 mL of the nanoparticle suspension to a 1 cm 
polystyrene cuvette and scanning in a Brookhaven 90 Plus Particle Size Analyzer with 2 scans of 
20 minutes each. Number, volume, and intensity-weighted populations were used to quantify the 
particle size distribution. 
4.2.7 Transmission Electron Microscopy 
TEM samples were prepared by adding a single drop nanoparticle suspension onto a 
formvar coated copper grid and removing most of the drop using filter paper after 5 minutes. A 
single drop of 2% aqueous phosphotungstic acid was then added onto the grid for 50 seconds 
before being removed with filter paper to negatively stain the grid. TEM imaging was carried out 
on a Phillips CM10 Transmission Electron Microscope equipped with a lanthanum hexaboride 
filament saturated at an accelerating voltage of 60 kV. 
4.2.8 Determination of Encapsulation Efficiency and Mass Yield of Doxorubicin 
The suspension of doxorubicin loaded Curdan-g-PEG nanoparticles was concentrated in 
amicon filtration units at 4000 RPM for 20 minutes to remove water and free Doxorubicin and 
the retenate dissolved in 2 mL of DMSO by pipetting up and down vigorously. One milliliter of 
the resulting solution was diluted in 5 mL of DMSO and the sample was read in triplicate (100 
µL) in a 96 well microplate at 480 nm. The absorbance was converted to concentration and the 
encapsulation efficiency determined by dividing the actual concentration by the ideal 
concentration. The mass yield was determined by normalizing the encapsulation efficiency by 
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the drug loading percentage. Displayed data is the average of three release runs with error bars 
displayed from the standard deviation. 
4.2.9 In Vitro Release of Doxorubicin from Nanoparticles 
Eleven milliliters of nanoparticle suspension in distilled water was added to a 3.5 kDa 
dialysis tube and dialyzed against 1.75L of distilled water for 3 hours to remove free drug. One 
mililiter of the washed nanoparticle suspension was added to 12.5 mL of distilled water and read 
in triplicate (100 µL) in a 96 well microplate at 480 nm to determine the 100% release condition. 
The remainder of the suspension in the dialysis tube (10 mL) was added into 125 mL of distilled 
water stirring at 37 °C. The release system was sealed with parafilm and covered in foil to avoid 
evaporation and doxorubicin degradation. Three 100 µL samples were taken at regular intervals 
and read in triplicate at 480 nm in a 96 well microplate. Constant volume was maintained in the 
release medium. Mean absorbance values were compared to the 100% release condition to 
determine the percent release. Displayed data is the average of three release runs with error bars 
displayed from the standard deviation. 
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4.3 Results and Discussion 
The synthesis of Curdlan-g-PEG was carried out as shown in Figure 14 and verified by 
NMR spectroscopy. The Curdlan-g-PEG 1H-NMR and 13C-NMR spectra reveal new peaks at 
3.47 ppm and 70.13 ppm respectively as well as some additional peaks in the 1.0-2.0 ppm range 
(Fig. 15) attributable to residual DCC difficult to remove by repeated ether washes. The two 
large signals present after dialysis and purification may be correlated to one another using 
HMQC analysis (Fig. 16) and correspond to the signals observed for NMR scans of the pure 
Carboxylated PEG and the literature for PEG derivatives145. Calculation of the degree of 
substitution is possible from comparison of the PEG and curdlan carbon peaks on the 13C-NMR 
scan. Comparison of the intensities of the PEG and C(6) peaks yields a degree of substitution of 




Figure 14. Reaction Scheme for PEGylation of Curdlan. (Top) Carboxylated PEG is reacted 
with DCC to produce the DCC-activated PEG derivative. (Bottom) Reaction of the activated 





Figure 15. Proton and Carbon NMR Spectra of Curdlan-g-PEG and Curdlan. (Top) 1H-
NMR scan of Curdlan (Bottom) and Curdlan-graft-PEG (Top) showing the presence of a 
significant PEG peak after grafting at 3.47 ppm. (Bottom) 13C-NMR scan of Curdlan (Bottom) 
and Curdlan-graft-PEG (Top) showing the PEG peak at 70.13 ppm.  
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Figure 16. HMQC scan of Curdlan-graft-PEG. The correlation of six 13C-NMR signals in the 
Curdlan ring to the 1H-NMR signals and the correlation of the signals for PEG. 
 
DLS analysis on empty and doxorubicin loaded Curdlan agglomerations and Curdlan-g-
PEG nanoparticles formed by nanoprecipitation gave insight into the relative populations of 
particle sizes and the effect of PEGylation. With pure Curdlan and Doxorubicin agglomerations, 
DLS was inconclusive as the particle sizes were greater than the upper limit and the particles 
settled quickly in distilled water whereas number weighted DLS analysis of the Curdlan-g-PEG 
system revealed that PEGylation yielded stabled nanoparticles with a size of 93.1 nm (Fig. 17A) 
when Curdlan-g-PEG was loaded with 20% Doxorubicin compared to the empty particle size 
that averaged 53.3 nm.  Nanoparticles were stable for greater than 7 days in distilled water. 
Intensity (Fig. 17B) and volume (Fig. 17D) weighted analysis revealed the presence of some 
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larger aggregations among the nanoparticles with particle sizes as high as 392.4 nm but these 
larger particles were not visible on TEM micrographs, suggesting they represent a minority in 
the population. The lognormal number population density (Fig. 17C) provides the nanoparticle 
size distribution with a mean particle size of 109.9 nm. 
The initial drug loading percentage greatly affected the nanoparticle sizes determined by 
DLS. No difference was observed between 10% and 20% but 40% drug loading caused the 
particle size to increase to 400 nm and the particles to settle in distilled water. Since doxorubicin 
was capable of forming nanoparticles with particle sizes less than 75 nm at similar 
concentrations used in the polymer nanoparticles, the increased particle size over both free 
doxorubicin and free Curdlan-g-PEG suggested a coating of doxorubicin nanoparticles in the 
polymer as the main mechanism of interaction. It is postulated that the Curdlan-g-PEG aids 
aggregation of doxorubicin by providing a water stable coating but higher concentrations of 
doxorubicin yield particles that are too large to remain stable. The nanoparticle architecture is 
hypothesized to consist of a doxorubicin nanoparticle upon which the Curdlan backbone 
experiences hydrophobic interactions and PEG grafts align outwards to provide a water stable 
shell (Fig. 13). 
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Figure 17. DLS Study of Curdlan-g-PEG Nanoparticles. (A) Number weighted population 
density for Curdlan-graft-PEG loaded with 20% Doxorubicin. (B) Intensity weighted population 
density. (C) Lognormal number population density. (D) Volume weighted population density. 
 
TEM verified the particle sizes determined by DLS (Fig. 18) and the nanoparticle 
architecture proposed (Fig. 13B). Since the negative stain, phosphotungstic acid, used in the 
analysis is highly hydrophilic and electron dense, the hydrophilic PEG portion of the 
nanoparticles should appear darker due to increased electron density and doxorubicin and 
Curdlan portions of the nanoparticles should appear lighter. It was found that the presence of the 
doxorubicin center was clearly visible as bright white spots with a coating of a darker material 
(Fig 18A). No presence of bright white spots without such coating were visible on TEM samples, 
suggesting high encapsulation efficiency. Upon closer inspection of the nanoparticles the outer 




postulated to be tightly packed curdlan backbone around the doxorubicin center and the outer 
darker layer fully extended PEG chains that provide water stability. Upon rudimentary 
calculation, the size of the dark PEG shell correlates well with the expected size of fully 
extended 5000 Da PEG chains. TEM thus correlates well with the nanoparticle architecture 
proposed (Fig. 13). In addition, TEM scans reveal the highest population of nanoparticles with a 
measurable size of 100 nm in close correlation with DLS results. Very few large aggregations, 
corresponding to larger scattering centers revealed by volume and intensity weighted DLS scans 




Figure 18. TEM Study of Curdlan-g-PEG Nanoparticles. (A) 20% Doxorubicin nanoparticles 
of Curdlan-graft-PEG appear as a bright Doxorubicin center with a coating of more electron 
dense material. (B) The coating is revealed to be multi layered with a compressed inner layer 






Doxorubicin loaded pure Curdlan and Curdlan-g-PEG nanoparticles were screened for 
encapsulation efficiency using UV-vis spectrophotometry. Prior to measurement, Doxorubicin 
not encapsulated was removed by Amicon centrifugation. The resulting retenate was dissolved in 
DMSO and diluted within an appropriate range for the calibration of the Doxorubicin. After 
determining the drug concentration and comparing to the ideal concentration, the encapsulation 
efficiencies for the varying drug loading percentages were determined for pure curdlan and 
Curdlan-g-PEG (Fig. 19). The Curdlan-g-PEG system attained similar encapsulation efficiencies 
as pure Curdlan. Therefore, PEGylation allowed for stable nanoparticle formation while 
maintaining the inherent drug encapsulating capability of pure Curdlan. Encapsulation efficiency 
is inherently dependent on the initial drug loading value and as such, this data was normalized by 
the drug loading percentages to determine the mass yield, a measure of the percentage of drug to 
polymer attained in the final suspension (Fig. 20). Since the nanoparticle system with 40% drug 
loading was unstable in water, the 20% loading condition is compared to other systems. The 
mass yield of 4-5% for the 20% loaded nanoparticle system is considerably high in comparison 
to other literature using Curdlan130 and other encapsulation methods that typically produce mass 
yields around 2-3%140 but the encapsulation efficiencies are significantly lower. Lower 
encapsulation efficiency can be explained by the need to use lower concentrations of 
Doxorubicin and polymer to enable nanoparticle formation by the nanoprecipitation method.  
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Figure 19. Encapsulation Efficiencies of Curdlan-graft-PEG and Pure Curdlan. The 
Curdlan system quickly aggregated and crashed upon precipitation and the Curdlan-graft-PEG 
system was stable indefinitely with similar encapsulation efficiency. 
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Figure 20. Mass yields of Curdlan-graft-PEG and Pure Curdlan. Encapsulation Efficiency 
normalized by the initial drug loading percentage. 
 
In Vitro release was carried out in distilled water at 37 °C. The nanoparticles showed a 
release rate of nearly 100% of the releasable drug within 24 hours but during the initial wash to 
remove free drug, the nanoparticles became unstable. From this it can be concluded that the 
system was reliant on free Doxorubicin for stability although there were no visible coatings or 
networks of Doxorubicin on TEM micrographs to support this hypothesis. In addition to the 
reliance on Doxorubicin, the nature of the micelle constructed from graft copolymer means that 
the system is less amphiphilic than more commonly used block copolymer systems140. 
Consequently, it is postulated that, when exposed to the osmotic pressure of dialysis, the 
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nanoparticles have a tendency to break apart and aggregate into less ordered structures. Despite 
the issues with nanoparticle stability, it was possible to remove nearly 50% of the loaded 
doxorubicin as tested by UV-Vis spectrophotometry of periodically sampled distilled water from 
the release medium (Fig. 21). Experimentation with the degree of substitution to attain a better 
hydrophilic-lipophilic balance in the future could improve particle stability.  
 
Figure 21. Release profile of Doxorubicin from Curdlan-graft-PEG nanoparticles. 
Doxorubicin was released at a constant rate for 24 hours with a maximum release of 50%.  
 66 
 
The developed nanoparticle system is a significant development in Curdlan nanoparticle 
systems as it is the first system to utilize a Curdlan copolymer wherein the hydrophobicity of 
Curdlan is used to create the drug association. Other systems have utilized sulfonylurea or 
cholesterol as the hydrophobic moiety and carboxymethylated curdlan as the water-stabilizing 
moiety33, 131. The Curdlan-g-PEG system developed herein may also be the first Curdlan 
nanoparticle system that could allow the transport of the immunomodulatory behavior of Curdlan 
to the site of a tumor as all other systems bear Curdlan on their surface, making them naturally 
immunogenic. 
4.4 Conclusions 
The present study demonstrated the feasibility of Curdlan-based nanoparticles for 
controlled drug release applications. A Curdlan-g-PEG copolymer was successfully synthesized 
by DMAP mediated DCC-ester formation using a monofunctional carboxylated PEG. A degree 
of substitution of 1.8 PEG chains per 100 glucopyranose units was obtained successfully. 
Nanoparticles with an average size of 109.9 nm were obtained with excellent stability in distilled 
water for greater than 7 days, demonstrating that PEGylation of curdlan can produce stable 
nanoparticles. The nanoparticle architecture appeared to be a central core of doxorubicin coated 
with a Curdlan backbone and fully extended PEG grafts in a triple layer structure. Encapsulation 
efficiencies comparable to pure Curdlan were obtained and high mass yields (4-5%) comparable 
to Curdlan solid lipid nanoparticles and well-recognized PLGA-PEG systems resulted. 
Doxorubicin released at a sustained rate for 24 hours. These results suggest that the PEGylated 
Curdlan is a viable approach to form nanoparticle delivery systems that may be useful in the 
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development of controlled release drug delivery applications that are also capable of providing 
immunotherapeutic action. 
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5.0 Formulation of Curdlan and DNA Multi-Phase Liquid Crystalline Gels 
5.1 Introduction 
 This section of the thesis describes a new Curdlan hydrogel gene delivery platform that 
has allowed for triggered release of DNA from a hydrogel formed into a variety of shapes and 
sizes bearing the unique ability to partition crystalline and non-crystalline polymer and DNA. As 
described in section 3.0, this work is intended as a new approach that overcomes the need for 
homogenous polynucleotides in the formation of Curdlan gene delivery systems. Pure, 
unmodified Curdlan and double helical DNA isolated from salmon testes were chosen for this 
application.  The use of unmodified Curdlan is an improvement over previous systems where the 
inherent water insolubility of Curdlan had to be overcome through functional grafts. Double 
helical salmon DNA was chosen as the model polynucleotide because it has very high molecular 
weight and would thus be most susceptible to crystallization. The LCG was formed by exposure 
of a mixture of Curdlan sodium hydroxide solution and aqueous DNA to aqueous calcium 
chloride. Macroscopic gels were formed using dialysis tubing and smaller structures were 
formed by drop-wise addition to stirring aqueous calcium chloride. The structures were 
characterized using polarized light to identify crystallinity, TEM to investigate smaller 
structures, and UV-visible spectrophometry to identify DNA concentrations via absorbance.  
The present system is highly significant to Curdlan and gene delivery research as it 
allows the simultaneous co-gelation of DNA and Curdlan to form a gel shaped into a number of 
forms and sizes, capable of triggered release, and where the crystalline and non-crystalline 
phases of each material partition in the overall architecture. Partitioning amorphous material in 
the gel ensures that at least a portion of the payload DNA to remain in its amorphous state and 
avoid denaturation.  
 69 
5.2 Experimental Methods 
5.2.1 Materials 
Curdlan (~90 kDa) was obtained from Wako Pure Chemical Industries.  Sodium 
hydroxide was purchased from Caledon Laboratory chemicals, calcium chloride anhydrous salt, 
phosphotungstic acid (PTA), trisodium citrate salt and dialysis membrane were purchased from 
Fisher Scientific (Flat Width 45mm and 12,000 to 14,000 Da MWCO).  DNA sodium salt (1300 
kDa) from salmon testes was purchased from Sigma-Aldrich.  Materials were used without 
further purification. Formvar coated transmission electron microscopy (TEM) grids were 
purchased from Canemco & Merivac (100 mesh copper grids).  Linear polarizer sheets (2” x 2”) 
were purchased from ThorLabs, Inc. and used to create the crossed nicols effect.   
5.2.2 Macroscopic Cylindrical Gel Formation 
Curdlan was dissolved in 0.4M sodium hydroxide solution at a concentration of 70 
mg/mL (7% w/v).  DNA was dissolved in deionized water at a concentration of 15 mg/mL (1.5% 
w/v).  Aqueous DNA solution was mixed with Curdlan solution at different volume ratios to 
obtain 5%, 10% and 20% DNA/Curdlan samples.  Thereafter, 12 mL of these solutions were 
added into a dialysis membrane, which was molded to form a cylindrical shape using two caps of 
diameter 29.6 mm.  The dialysis tube was then immersed in 100 mL of 10% aqueous calcium 
chloride solution for 3 days.  The gels were extracted by cutting out the dialysis membrane and 
cross-sectional slices of 5 mm were obtained for imaging.  Imaging under visible light was 
carried out using a Sony Cyber-shot DSC-P150 digital camera. For polarized light analysis, two 
2” x 2” linear polarizer sheets were placed orthogonal to each other on either side of the gel 
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cross-section to create crossed nicols. Images were taken using an Olympus PEN EPL-1 digital 
SLR camera.  
5.2.3 DNA Concentration Profile 
Cross-sectional gel slices used for imaging were further sliced longitudinally into 2 mm 
thin slices to determine the DNA distribution in the gel.  The thin slices were dissolved in a 5% 
sodium citrate solution at a concentration of 10 mg/mL to chelate the calcium ions.  The 
distribution of DNA in the gels was determined by adding 300 uL of the final solution in 
triplicate to a 96-well microplate and reading the absorbance at 260 nm on an Epoch UV-Vis 
spectrophometer. 
5.2.4 Hydrogel Swelling 
 The swelling and drying capability of the gel was tested by leaving a piece of Curdlan gel 
in ambient air for 48 hours until the gel was completely dry and solid, losing 90% of its initial 
mass. The gel was then immersed in distilled water for 48 hours and subsequently re-dried to 
demonstrate another swelling cycle. To produce the swelling curve, the gel was measured every 
24 hours using an analytical balance. 
5.2.5 Spherical Gels 
In order to formulate spherical gels of Curdlan and DNA, Curdlan was dissolved in 0.4M 
sodium hydroxide at a concentration of 15 mg/mL and DNA was dissolved in deionized water at 
a concentration of 15 mg/mL.  These two solutions were mixed in various proportions to obtain 
samples of 0%, 25%, 50%, 75%, 100% DNA.  This mixture was then slowly added drop-wise to 
magnetically stirring solution of 10 wt % aqueous calcium chloride. The solutions were allowed 
to stir for 1 hour.  Gels were formed in the presence of DNA, with decreasing rigidity as DNA 
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concentration decreased.  Pure Curdlan sample did not produce any visible structure.  These 
samples were flattened between a microscope slide and a cover slip and imaged under 50x 
magnification on an Olympus BX-50 polarized light microscope.  
5.2.6 Micro and Nano structures    
Solutions of Curdlan and DNA were prepared at various concentrations, lower than 
previously used.  These solutions were mixed in a 50/50 ratio and added to stirring 10% aqueous 
calcium chloride in a drop-wise manner.  TEM samples were prepared by extracting a drop of 
sample onto the TEM grid and letting the polymer absorb for 3 minutes followed by filter paper 
blotting to remove excess solution.  Staining was performed by exposing the samples to 2% PTA 
for 30 seconds.  The samples were dried in ambient conditions overnight and imaged the 
following day.  The most representative images were presented.   
5.2.7 Triggered Release of DNA    
The release characteristics of the DNA from the LCG were tested by exposing a slice of 
the 5% DNA macroscopic cylinder to either distilled water, 1% aqueous sodium citrate, or 
alternating between the two. Three hundred microliter samples were taken every 30 minutes and 
added in triplicate into a 96-well microplate and read at 260 nm on an Epoch UV-Vis 
spectrophotometer. The samples were replaced with fresh release medium. In the case of the 
alternating release medium, the medium was switched every 2 hours with a five-minute wash in 
distilled water upon each switch. 
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5.3 Results and Discussion 
To begin investigation of co-gelation of Curdlan and DNA, macroscopic gel cylinders 
were formulated with DNA weight percentages of 0, 5, 10, and 20%. When the initial solution 
containing the appropriate mixture of Curdlan and DNA was exposed through dialysis to 10% 
aqueous calcium chloride for 3 days, calcium cations diffused into the polymer solution and 
cross-linked peripheral hydroxyls on the Curdlan monomers, leaving a concentration gradient of 
polymer from highest to lowest on the outside of the cylinder to the center123. Resilient LCG 
cylinders resulted with concentric turbid rings observable when the gel is sliced in cross-section. 
When the initial solution contained 1.5 wt % aqueous DNA, a similar gel was obtained with a 
different distribution of concentric rings. Figure 22 shows the different macroscopic cylindrical 
gels formed when cut into 5 mm cross-sections as well as the same gels viewed under double-
polarized light (crossed nicols).  
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Figure 22. Curdlan and DNA Liquid Crystalline Gel Cylindrical Cross-sections.  
Concentrations are 100% Curdlan, 5% DNA, 10% DNA, and 20% DNA as seen through visible 
light (Top) and crossed nicols (Bottom). 
 
The pure Curdlan system showed characteristic concentric rings under visible light where 
the outer semi-transparent peripheral and inner semitransparent ring represented tightly packed 
LCG Curdlan and the white ring represented amorphous Curdlan123. When viewed under crossed 
nicols, the outer peripheral showed alternating colors characteristic of birefringence through an 
anisotropic crystal with the presence of orthogonal dark lines (isogyres) visible across the region. 
The presence of the dark isogyres and a lighter center of the gel demonstrated that, although 
similar in appearance to the amorphous ring under visible light, the region contained crystalline 
Curdlan. The gels formed by Dobashi123 were thought to contain a lower density of Curdlan 
mesogens in the center due to the concentration gradient but these previously formed gels did not 
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have the white center observed. Since the molecular weight of the Curdlan in the present study 
was lower, compounded with the lower concentration in the center, less crystalline order may 
have resulted in the center of the present gel, causing visible light to be obscured and the white 
center to be present. 
Introduction of DNA into the cylindrical gels caused a partitioning of the DNA into the 
amorphous and crystalline phases. Crystalline DNA formed a homogenous crystalline network 
with Curdlan along the periphery of the gels as seen by the darkening of the isogyre lines under 
crossed nicols, indicative of an anisotropic crystal. DNA was also present in an isotropic 
amorphous form as seen by darkening and expansion of the amorphous ring with increasing 
DNA concentration and loss of crystallinity previously indicated by the isogyres in the center of 
the gel. This behavior of DNA partitioning into anisotropic crystalline and isotropic amorphous 
has been observed in pure DNA LCG139 and this remains in co-gelation with Curdlan. 
To investigate the DNA profile in the gel to verify the conclusions from polarized light 
analysis, aqueous sodium citrate was used to dissolved longitudinal slices of the gel such that the 
DNA concentration could be tested by absorbance along multiple points of the gel radius. Using 
2 mm slices and dissolving in sodium citrate at a constant concentration, absorbance at 260 nm 
reveals the profile for the different DNA weight percentages as shown in Figure 23. 
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Figure 23. Concentration Profile of DNA in Cylindrical Gels. Absorbance at 260 nm of 
Longitudinal Gel Slices shown the presence of rings of DNA in the center and peripheral of the 
LCG. 
 
The profile reveals that at DNA concentrations greater than 10% the presence of two 
concentrations of DNA is visible, representing the amorphous and crystalline phases observed 
under polarized light. The profile also confirms that the DNA and Curdlan form a homogeneous 
crystalline matrix as under both polarized light and visible light there is no visible partitioning in 
the peripheral of the gel but the DNA concentration is revealed to be high. 
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 The swelling of the macroscopic gels was tested to verify the nature of the gel as a 
hydrogel, one that incorporates water into the matrix. After performing two drying and swelling 
cycles on the pure Curdlan sample, the result shown in Figure 24 below was obtained. 
 
Figure 24. Swelling and Drying Characteristics of the Curdlan LCG. 
 
The Curdlan LCG was capable of complete swelling after initial drying and was able to then 
return to a dried state of 10% of the initial weight, thereby demonstrating that the Curdlan LCG 
was indeed a hydrogel containing 90% water in its final structure. 
Curdlan and DNA were also simultaneously gelled into elastic spherical gels on the 
millimeter length-scale when added drop-wise into stirring aqueous calcium chloride. Mixing 
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different ratios of Curdlan and DNA (100/0, 75/25, 50/50, 25/75, 0/100 DNA/Curdlan) caused 
the formation of markedly different structures. The 100/0 case caused the formation of tightly 
packed spherical precipitates whereas 75/25 and 50/50 cases yielded larger spherical gels that 
had a white center similar in appearance to the pure DNA and a semi-transparent outer coating of 
Curdlan. The 0/100 system was not capable of forming spherical gels. Figure 25 shows the 
spherical gels under visible and polarized light (crossed nicols). 
 
Figure 25. Curdlan and DNA Spherical Gels.  Different concentrations of Curdlan and DNA 
as seen under visible light (Top) and polarized light (Bottom) Scale bars are 1mm. 
 
The 100% DNA system formed a highly dense, optically opaque spherical gel. Under crossed 
nicols the system was revealed to be amorphous due to the lack of birefringence patterns. The 
structure was markedly different when 25% Curdlan was incorporated. No longer optically 
opaque, the gel showed the characteristic isogyre pattern representative of an anisotropic 
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crystalline structure. The center of the 75/25 gel under polarized light showed a blurring of the 
orthogonal isogyres, representative of a more isotropic, amorphous core. Further incorporation of 
Curdlan in the 50/50 sample caused a darkening of the isogyre pattern and more definition in the 
central region, characteristic of an overall increase in crystallinity. Therefore, the spherical gels 
are formed with 75/25 and 50/50 mixtures with a tendency for isotropic DNA to localize to the 
center and increasing levels of Curdlan to increase the overall crystallinity. In addition, the DNA 
acted as a nucleating center for the formation of the spherical gel as the pure Curdlan samples 
could not adequately hold their shape. 
 Lower concentrations of DNA allowed the formation of nano- and microstructures 
observable through TEM but not possible to screen for crystallinity using the concentional 
method. Using equal volumes of the Curdlan and DNA concentrations specified, the structures 
shown in Figure 26 were created. 
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Figure 26. Curdlan and DNA nano- and micro-structures. Addition of equal volumes of 
Curdlan and DNA at different concentrations form a variety of structures. White scale bars are 
500 nm and black scale bars are 2000 nm. 
 
At the 30 mg/mL Curdlan level, TEM revealed the presence of a fibrous network of Curdlan 
with a fiber width of 20 nm. When repeated with 0.1 mg/mL DNA mixed in, 1.75 µm core-shell 
microparticles were observed with a white center and a dark outer ring. The white center was 
postulated to be a solid core of amorphous DNA and the outer ring more crystalline Curdlan due 
to the presence of fibrous striations on the periphery.  This structure appeared to be the 
microscale analogue of the spherical gels. The ability to miniaturize the system was a remarkable 
phenomena. Introduction of higher concentrations of DNA caused a characteristic increase in the 
average microparticle size to 4 µm and upwards to 9-10 µm. At the 10 mg/mL Curdlan level, the 
pure Curdlan system showed a similar fibrous network with smaller features and a fiber diameter 
 80 
of only 5-10 nm. Incorporation of DNA typically yielded the formation of particles and in the 
case of 0.1 mg/mL DNA, the presence of globular spheres within the fiber network was 
observed. Further increases in DNA concentration caused the formation of discrete nanoparticles 
with a fibrous nature and eventually the formation of a rigid rod-like structure wherein individual 
rods had a hydrophilic periphery and a hydrophobic core as observed by the contrast from PTA 
staining. Without Curdlan, DNA initially formed small particulates (200 nm). Higher 
concentrations of DNA caused the formation of highly crystalline structures beginning with 
hexagonal crystallites and evolving to DNA crystallites forming fractal patterns.  
 It was thus confirmed at the nanoscale that DNA acted as a nucleating center for the 
formation of particles. This was caused by its higher molecular weight leading to a higher rate of 
crystallization. After initial particle formation with DNA, the Curdlan could deposit on the 
surface as a stabilizing layer. In the case of lower concentrations of Curdlan where larger 
particles could not form, fibrous structures appeared to grow from the nucleating centers. With 
enough DNA, the nanoparticle-laden fibers evolved into rigid rods. 
 The ability to control the architecture of the LCG by simply changing concentration or 
altering the method of addition to aqueous calcium chloride allows the LCG system to be highly 
applicable to gene delivery. However, in order to be therapeutically relevant, the DNA had to be 
releasable in a bioactive state. As the absorbance of a DNA solution at 260 nm is representative 
of double helical DNA, the release of DNA was measured using spectrophotometry. Using the 
macroscopic gel cylinders as a convenient model for release, it was initially determined that no 
release of DNA occurred in distilled water as seen in Figure 27. This was a promising result as it 
allowed for investigation of controlled release phenomena. 
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Figure 27. Triggered release of DNA from Curdlan/DNA Macroscopic Cylinders. Triggered 
release is possible in 1% sodium citrate and no release is observed in water. Inset plot shows the 
phenomena triggered on the same sample. 
 
When another gel was exposed to 1% sodium citrate the release curve was drastically different. 
The sodium citrate caused chelation of the calcium cations, breaking the cross-links holding the 
hydrogel together. This phenomenon took two hours to begin allowing for both delayed and 
triggered release. It was possible to cause the triggered release effect from the same gel that had 
been hydrated in water as well, demonstrating that the gel must be hydrated for two hours before 
any release occurs, regardless of whether hydration occurs in water or the sodium citrate 
medium. As the gels dissolved completely after the release was completed, the release profile 
can be taken as percent release. 
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5.4 Conclusions 
 The demonstration of the co-gelation of Curdlan and DNA in the formation of unique 
structures ranging from nano- and microparticles to millimeter scale spherical gels and 
macroscopic cylinders controllable by concentration demonstrated the creation of a new multi-
phase hydrogel system. Using the macroscopic cylinders, the nature of the system as a LCG was 
verified and the DNA profile showed the homogeneous crystallization of Curdlan and DNA. 
Since similar behavior was observed at the millimeter scale, it is believed that even the nano- and 
microscale systems are LCG’s although this could not be proven using conventional means. The 
homogeneous crystallization of Curdlan and DNA down to the nanoscale demonstrated a new 
approach to forming polysaccharide-polynucleotide inclusion complexes. 
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6.0 Conclusions and Recommendations 
6.1 Concluding Summary 
 This thesis began with an overview of the basics of drug delivery technologies and an 
introduction to polymer nanoparticles and hydrogels. A comprehensive literature review then 
introduced all the relevant work on Curdlan and 1,3-Beta-Glucans. Drawing from the research 
milestones applicable to drug delivery, research objectives were established to 1) Demonstrate 
the feasibility of Curdlan as the central core in a core-shell nanoparticle system through graft 
PEGylation and 2) Demonstrate the formation of a new type of hydrogel LCG that provided a 
new approach to Curdlan and polynucleotide inclusion complexes. Together, these objectives 
sought to establish Curdlan as a natural polysaccharide platform for drug delivery that could add 
a beneficial immunotherapeutic effect. 
With the polymer nanoparticle system, PEG was successfully grafted onto Curdlan which 
allowed nanoparticle formation and the creation of a nanoparticle architecture with appropriate 
size to utilize the EPR effect for targeting and the ability to extract most of the encapsulated 
drug. Drawbacks of the system were instability during dialysis release. Despite this, Curdlan was 
successfully demonstrated as the core of a nanoparticle drug delivery system. 
With the hydrogel LCG system, Curdlan and DNA were simultaneously gelled using 
calcium chloride to create macroscopic gel cylinders exhibiting LCG behavior and showing a 
unique partitioning of crystalline and amorphous material. The gel cylinders were evaluated to 
demonstrate that the structure contained 90% water and that the DNA formed a homogeneous 
crystalline network with Curdlan. The gels also both delayed and triggered release using sodium 
citrate as a chelating agent. The system was miniaturized to create spherical gels showing similar 
crystallinity phenomena to their macroscopic counterparts. Further miniaturization allowed the 
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demonstration of a suite of new architectures dependent on concentration ranging from 
nanofibers to microparticles. Overall, the research in this area was highly successful as it 
demonstrated a new type of multi-phase LCG and a new approach to forming Curdlan-
polynucleotide drug delivery systems. 
In terms of the overall trends in Curdlan research, two streams were observed in the 
literature review including 1) Research into the pharmacological applications of Curdlan using 
its potent immunotherapeutic effects and 2) Research into structural applications of Curdlan 
using the triple helical architecture to create structures ranging from resilient gels for food 
applications to nanoscale scaffolds for development various nanostructures. Drug delivery 
applications, especially those utilizing nanoscale phenomena were identified as an area where 
these two research streams coalesce.  
With nanoparticle drug delivery systems now moving beyond clinical trials into wide 
spread use (ex. Doxil™ chemotherapeutic liposomes) it has been necessary to make use of the 
unique properties offered by natural polysaccharides in this field. Curdlan 1,3-Beta-Glucans, 
with their immense pharmacological potential, have been identified in the literature as a 
promising direction but until this present work Curdlan was not used to its fullest potential, being 
used only as a stabilizing agent. This work demonstrated that multi-functional Curdlan can 
exceed the capabilities of more common synthetic polymers such as Poly(lactic acid) for the 
purposes of nanoparticle drug delivery, thus contributing significantly to the advancement of the 
potential of Curdlan and the field of nanoparticle drug delivery. 
The unique triple helical structures formed by Curdlan and other 1,3-Beta-Glucans have 
allowed for unique applications not attainable from synthetic polymers such as the formation of 
polynucleotide inclusion complexes. These unique helical structures have been shown to have 
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immense potential in gene delivery provided the limitation of requiring homogeneous 
polynucleotides is overcome. The presently discussed work has been highly significant in 
expanding the potential applications of Curdlan in gene delivery by expanding the array of 
methods to create inclusions complexes with polynucleotides using a crystallization approach as 
opposed to the commonly studied re-naturation approach.  
6.2 Recommendations for Future Work 
 With the demonstration of Curdlan as a viable platform for polymer nanoparticle drug 
delivery, experimentation with the Curdlan-g-PEG system could be pursued further in order to 
obtain a better HLB that improves stability during drug release. As Curdlan has been 
demonstrated to be sufficiently hydrophobic for drug encapsulation the grafting of different 
hydrophilic moieties could produce more favorable results as well. The demonstration of 
polymer nanoparticle formation with a copolymer of Curdlan and water-soluble Dextran would 
be a milestone in the application of natural polysaccharides for polymer nanoparticle formation 
over synthetic polymers.  
 With the demonstration of the capability of Curdlan and DNA to form multi-phase 
hydrogel LCG it is possible to pursue a whole suite of new drug delivery systems using the co-
gelation of Curdlan and DNA as opposed to the formation of molecular inclusion complexes. 
Investigation of the molecular weight effect would be the most important research direction, as 
the incorporation of smaller DNA strands would drastically change the nano- and microscale 
architectures observed. Additionally, new methods to expose the polymer solution to calcium 
chloride could allow for the formation of new structures. An example could be the use of a 
double emulsion scheme to allow for the formation of micro-droplets prior to exposure to 
calcium chloride. Such a system may not use DNA as a nucleating center and instead form a 
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homogeneous, solid microsphere. The successful research presented herein has been a 
demonstration of the potential of Curdlan as a new platform for a variety of drug delivery 
systems. 
 In summary, the significant works discussed herein could be built upon by: 
1. Establishing an improved hydrophilic-lipophilic balance in the Curldan-g-PEG polymer 
by modulating the grafting frequency to improve nanoparticle stability. 
2. Investigate the use of water-soluble natural polysaccharides to replace synthetic PEG to 
create a fully natural polymer system with improve stability. 
3. Investigate the effect of molecular weight on the formation of nano- and microstructures 
in the formation of Curdlan and DNA LCG. 
4. Discover new methods to expose Curdlan/DNA solution to calcium chloride (ex. Double 
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